corporate responsibility report feel better live longergsk corporate responsibility report gsk gsk mission improve front cover image donated antiparasitic treatments quality human life enabling people million schoolage children developing world helping combat effects feel better live longer intestinal worms cycle poverty contribute intestinal worms one report describes progress neglected tropical diseases targeting research funding making operating partnerships dedicated operating unit established year business responsibly use report interactive pdf allows find information guide navigation buttons printfriendly pdf links navigate around report easily print icon navigation allows dynamic links within text indicated relevant links additional useful go main contents print whole document icon text shown section information including policy positions separate printfriendly pdf colour clicking take website gskcom search pdf information within document full screen mode web address related online site interested getting summary print pdf set view full screen opens new window responsible business performance suggest mode turn eg zoom read overview beginning navigation tabs print press esc full toolbar section find summary pages go preceding revealed return full screen mode clicking one tabs top press ctrll left take start go next section go overview sections summary return last visitedgsk corporate responsibility report inside report approach health behaviour people planet governance approach health behaviour people planet managing raenspdo nesnibgialigtieesment learn find learn find help read find developing innovative embedding values people thrive managing corporate responsibility read qa products improving behave ethically creating inspiring environmental impacts governance chairman access healthcare responsibly supportive working towards engage chief executive patients around world everything working environment carbonneutral value chain stakeholders overview overview overview overview governance create value improving healthcare ethical standards principles talent development carbon stakeholder engagement qa chairman global challenge sales marketing inclusion diversity water waste reporting chief executive officer innovative science working engaging employees managing impacts progress create value healthcare professionals health safety wellbeing engagement commitments moving forward access healthcare research practices reward recognition data summary diseases developing world manufacturing supply chain summary health wellbeing public policy assurance statement communities patient advocacy hivaids approach tax go approach section go health section g behaviour section go people section go planet section go governance see see see see see engagement section see gsk corporate responsibility report gsk scienceled global healthcare company making three primary areas business range products help pharmaceuticals vaccines consumer healthcare people feel better pharmaceuticals vaccines consumer healthcare live longer bn develop make medicines bn research make vaccines bn make innovative consumer values transparency treating range conditions children adults products four categories respect people integrity turnover including respiratory disease turnover protect infectious turnover total wellness oral care cancer heart disease epilepsy diseases including influenza nutrition skin health patient focus bacterial viral infections rotavirus cervical cancer measles portfolio includes wellknown hiv lupus skin conditions mumps rubella hepatitis polio brands sensodyne commercial success like psoriasis tetanus meningitis panadol horlicks group group group depends growing diverse business creating innovative new products people value making widely accessible operating efficiently able grow business operate countries turnover region employees region network manufacturing provide benefits patients sites large rd centres uk consumers employees usa spain belgium china shareholders society usa usa europe europe emap emap japan japan gsk corporate responsibility report create value delivering innovation context heart disease respiratory illnesses sustainability business performance next three years potential critically important deliver continued expanding access see opportunities challenges bring around new medicines patients innovation access products must products operating environment scientific produce profitable performance ensure access create value society research continuously uncovering new remain competitive funds invest understandings disease processes manufacture distribute people assets key element shareholders technologies four billion packs products environment appropriately rewards meanwhile worlds population countries around world innovation across patentprotected continues grow pressures extensive global presence striving branded products healthcare costs notable intensification make products widely accessible developed markets following recent possible macroeconomic downturn achieve objectives utilising western markets developed new assets executing strategic priorities innovation reimbursement approaches medicines operating business responsibly agree risksharing arrangements core business model use payers past five years made knowledge development intellectual significant progress delivery property create value researching adopted flexible pricing strategic priorities manufacturing making available products approaches reflect countries wealth improve peoples health wellbeing ability pay resulted significant developed balanced business increases demand products geographic diversity new platforms healthier society enables people live emerging economies growth particular advancement life fullest allowing latestage pipeline changes communities prosper sustained flow increase access products worlds rd model time also innovative products enables business leastdeveloped countries held simplified business reduce costs grow profits deliver improved returns price patented medicines region ensure retain longterm competitiveness shareholders developed world prices reinvest fifth profits commitment responsible values aim develop new products offer make sales territories back based business underlies everything significant improvements existing local healthcare infrastructure projects values applied across group treatment options therefore provide value focused integrating sustainable patients pay culture decisionmaking work governments insurers third parties developing new medicine takes many years values operate transparency invested billion core substantial investment able bring demonstrate respect people act research development new medicines scale significant resources expertise integrity patientfocused ask every vaccines consumer products required successful medicine require one employees embody values currently evaluating around investigational significant investment year period medicines diseases cancer diabetesgsk corporate responsibility report create value continued create value wider contributions primary contribution develop new products improve peoples health also create value global company assets shareholder returns making direct indirect economic social contributions countries intellectual property people operate infrastructure global diverse employee base consisting close employees deliver innnovative contract goods services significant strategic priorities benefits patients scale last year gsk spent around billion products expand suppliers across countries grow deliver simplify consumers society access company also contributes countries operate tax system charge taxation profits values amounted billion direct contributions support health wellbeing local transparency respect communities relevant gsk also made integrity patient focused reinvestment via global community programmes amount million per year finally believe create value acting catalyst partner organisations value new different perspectives groups bring thinking open working research charities academia companies progress highlights nongovernmental organisations bn st amount returned shareholders access medicines index number new product via dividends buybacks approvals usa past five years europe past five yearsgsk corporate responsibility report qa chairman chief executive officer despite challenging q operating responsibly tied setting new system allow q issues addressed researchers request access anonymised environment gsks commercial success beyond patientlevel data people participate delivered resilient aw commercial success inextricably research trials hope might help aw see implementation performance enhanced linked operating trustworthy bring advances healthcare plans commitments transparency responsible way strategy generate recognise commitment reflect clinical trials data continue returns shareholders diversified sales growth develop innovative desire ensure contribution lead commitments pricing look made substantive products make accessible many health gains building also harness manufacturing technologies people benefit possible first pharmaceutical company sign improve carbon footprint moves increase access way aligned alltrials campaign clinical trial transparency values transparency respect transparency commit make q board assess gsks integrity always putting patients clinical study reports publicly available responsible performance consumers needs first hope initiatives help bring positive returns shareholders scientific understanding inform medical cg corporate responsibility committee benefits patients wider society judgement ultimately improve patient care crc chair meets four times year real shared value receives reports progress four also saw another milestone areas outlined report health journey towards malaria vaccine publishing q progress company behaviour people planet late stage clinical trial results showing board continues constructively challenge making deliver longterm value rtss vaccine candidate help protect advise executive teams thinking african infants malaria aw rd made significant progress decisions seek deliver companys six new products regulatory cg delighted see gsk recognised strategic priorities responsible way review next three years gsk first access medicines index potential launch around new products sustaining top spot previous years q gsk setting longerterm globally good platform growth independent credible assessment commitments year patient benefit also continued work improve access medicines develop portfolios expand vaccines lets us know right track aw new commitments signal gsks long footprint emerging markets term strategic intent play part july group successfully resolved create shared value span entire sir christopher gent series longstanding legal matters chairman q gsk see strong us government primarily related business fully aligned strategy build established track record responsible performance historical sales marketing practices board recognises matters cg important outside aw commitments increase reflect company gsk today company understand priorities transparency clinical trials data demonstrate company continues take action hold us account effectively new values heart company levels improve procedures compliance commitments helping us addition sharing information sir andrew witty marketing selling embed values communicate delivering design results clinical trials chief executive officer based culture gskgsk corporate responsibility report progress report responsible shared value progress business performance health behaviour people planet year part commitment transparency topped access medicines committed provide access maintained rate despite reducing carbon index third time st anonymised trial data employees saying proud energy use since total approach see published clinical trials work gsk carbon footprint excluding authorised medicines raw materials increased see progress making driven higher inhaler sales see operate business next three years see potential bring around new responsibly reported medicines vaccines patients addition disclosing enabled employee volunteers results research publicly work countries across four areas see accessible clinical studies register pulse assignments reduced water consumption website receives average see operations compared almost visitors month delivered vaccine worlds see see largest mass vaccination programme pneumococcal disease increased proportion women gaviled introduction management pneumococcal vaccine pakistan cut total waste expected protect million revised code conduct compared see children year see see see external recognition received external recognition responsible business approach vigeo world carbon disclosure dow jones european uk indexes ftsegood index access medicines index project leadership index sustainability index ranked second world ranked top third time four consecutive years disappointed environmental social ftsegood index since ftse carbon disclosure included dow governance new ranking leadership index jones sustainability indexes highest scoring healthcare year reviewing company ftse performance criteria inclusion igsk corporate responsibility report commitments health innovating address currently unmet health needs improving access products irrespective people live ability pay moving forward controlling eliminating diseases affecting worlds vulnerable people adapt open innovation rd model currently used diseases continue work partners support strengthening healthcare developing world apply areas great unmet infrastructure anticipate could improve access healthcare medical need scientific challenge including infectious disease million underserved people vs alzheimers disease viiv healthcare continue increase access medicines developed invest development vaccines dont require continuous care adults children living hiv around world help forwardlooking commitments refrigeration making distribution easier less expensive unaids achieve goal reaching million people globally antiretroviral treatment reflect global health continue build core range products formats better meet needs people across globe including less able access build year commitment contribute fight malaria needs aligned afford products continued rd investment partnerships ground strategic priorities embed flexible pricing strategy innovative business help eliminate control ten neglected tropical diseases affect values models prescription medicines vaccines increase usage billion people including elimination lymphatic filariasis among less able access afford products continued investment rd ongoing product donations contribution london declaration neglected tropical diseases continue invest innovative crosssector partnerships commitments developed reduce child mortality continue support objective eradicating polio following significant engagement across providing vaccines unicef achieved business also consulted broad range external stakeholders global public behaviour putting interests patients people enabling people thrive health experts nongovernmental organisations consumers first driven values develop individuals deliver socially responsible investors everything backed robust mission commitments guide work policies strong compliance processes areas coming years enabling us build previous achievements measure c ontinue drive valuesbased approach sales marketing practices c ontinue promote inclusion diversity globally gsk communicate progress effectively across world interests consumers patients core continue create working environment inspires people grow begin reporting progress continue ensure interests safety patients consumers perform healthy resilient way new commitments next report paramount importance way design undertake extend volunteering opportunities bring positive change clinical trials product quality assurance monitoring communities global health providing individual development reporting adverse events ongoing product usage rigorously challenge need animal studies work minimise planet growing business reducing impact animal welfare investing development alternative environmental impact across studies sharing animalbased data value chain address un guiding principles human rights business across operations supplier relationships reduce overall carbon footprint vs transparent possible clinical trial data including publishing carbonneutral value chain clinical study reports without patientlevel data outcome trials reduce water impact across value chain vs medicines conducted gsk within appropriate process making available researchers access anonymised patientlevel data reduce operational waste vs scientific enquiry build sustainable supply lines nutrition portfolio work demonstrate gsk interactions patient advocacy groups local farmers improve agricultural practices improve yields commitments subject significant political stakeholders conducted appropriately ethically transparently competitiveness livelihoods legal intellectual property restraintsgsk corporate responsibility report health section overview improving healthcare global challenge innovative science create value access healthcare focus diseases developing world health wellbeing communities giving children better start hivaids life deworming read gsk corporate responsibility report health focus gsk playing leading role global want make products coalition pharmaceutical companies giving nongovernment organisations governments accessible affordable people global health organisations committed children work together control eliminate whos neglected tropical need generating better start diseases part commitment gsk donate returns need invest rd life million treatments anti parasitic treatment albendazole year deworming grow business help eliminate lymphatic filariasis lf million treatments fight intestinal worms school age children already donated three billion albendazole need new existing treatments increasing worlds doses fight two devastating diseases population grows ages many millions people developing intestinal worms affect billion countries still little access basic healthcare rising costs people worldwide one biggest causes ill health schoolage children significant concern everywhere continue evolve business estimated million children risk model address global challenges ensure business effects including stomach pains sickness sustainable malnutrition painful debilitating intestinal worms cause stunting gsk contributes improving health developing innovative controlling worms physical growth affect longterm valued products supporting disease prevention rd focused children investing brain development infected children often meeting unmet medical needs helping control eliminate future struggle attend stay alert school hindering education prospects diseases affecting worlds vulnerable people provided albendazole treatments investing expand portfolio new ways partnering million school age children deworming helps break cycle others tackle issues outside core business lack developing world healthier children healthcare infrastructure likely attend school get better education giving better aspire catalyst change beyond company many chance getting good jobs changes made business creating new headmistress local school ghana saysby controlling worms children models open innovation flexible pricing already investing future contributed wider change industrygsk corporate responsibility report overview glance innovative science create value access healthcare diseases developing world committed meeting least global polio eradication initiatives polio invested billion global research delivered vaccine worlds largest initiated joined london vaccine requirements procured development investigational mass vaccination programme declaration control eliminate unicef continue support medicines development including pneumococcal disease gaviled ten neglected tropical diseases initiative every country world targeting cancer diabetes heart disease introduction synflorix pakistan declared polio free see expected protect million see children year see bn see donated three billionth albendazole tablet fight lymphatic filariasis intestinal worms pledged donate health wellbeing put public domain compounds one billion tablets year communities showing promising starting points new see tb medicines following screening since developing countries market donated million promote entire pharmaceutical library access unit established health wellbeing two million compounds volume medicines supply least communities product see developed countries increased nearly financial donations million units see million see committed million tres cantos open lab foundation doubling hivaids funding independent research diseases viiv healthcare submitted regulatory developing world gsks open lab applications investigational see integrase inhibitor dolutegravir spearheaded firstofitskind established programmes training published latestage clinical trial publicprivate partnership produce community health workers least results showing rtss vaccine new combination hiv medicine developed countries meeting candidate help protect african paediatric use resourcelimited settings commitment reinvest profits infants malaria see made countries back see developing health infrastructure see gsk corporate responsibility report overview commitments post development agenda external perspective adapt open innovation rd model viiv healthcare continue currently used diseases developing increase access medicines care world apply areas great adults children living hiv current millennium development pleased companies unmet medical need scientific challenge around world help goals expire examined access medicine including infectious disease alzheimers unaids achieve goal reaching disease million people globally antiretroviral include targets health gsk index continue make progress active partner ensuring continued treatment improving access medicine people invest development vaccines focus health new framework developing countries glaxosmithkline dont require continuous refrigeration build year commitment developed post played important leadership role making distribution easier less expensive contribute fight malaria continued rd investment information gsks setting pace others follow continue build core range products partnerships ground position read reflected index formats better meet needs company retaining first place people across globe including less help eliminate control ten neglected ranking index companies able access afford products tropical diseases affect billion indeed following people including elimination embed flexible pricing strategy lymphatic filariasis closing gap gsk look forward innovative business models continued investment rd ongoing coming years observing prescription medicines vaccines product donations contribution gsk stepping pace increase usage among less able london declaration neglected progress order maintain access afford products tropical diseases leadership position continue invest innovative crosssector continue support objective partnerships reduce child mortality eradicating polio providing vaccines unicef achieved continue work partners support strengthening healthcare infrastructure anticipate could improve access healthcare million underserved people vs wim leereveld founder ceo access medicine foundation httpwwwaccesstomedicineindexorggsk corporate responsibility report improving healthcare global challenge poverty key issue barriers role significant progress many complex barriers treatments dont exist gsk responding modern medicine transformed challenges despite advances effective treatments millions lives many illnesses world health organization recommends needed diseases tuberculosis fatal countries need invest least us per capita per hepatitis c developing new treatments takes controlled treated many years costs millions pounds year guarantee access essential health services often low commercial returns diseases countries still meet target primarily affect developing countries since global child mortality affordability driving rate declined price lack resources prevent innovative governments people buying medicines science need price reductions help although creates value billion people live less day developed world developing world even cheapest medicines affordable challenge healthcare infrastructure ageing population lack infrastructure huge problems remain every year chronic disease lack eductation many developing countries lack adequate healthcare facilities staff numbers africa increasing millions people affected suffers global burden curable preventable illness access disease health workers medicines gdp spent luxembourg gdp spent eritrea resistance existing treatments healthcare highest per capita healthcare lowest per improving america per annum spend africa capita per resistance antimicrobials global challenge annum spend problem many diseases affecting affordability developing countries including malaria europe per people africa per people noncommunicable diseases children die children die age physicians physicians ageing populations rise obesity investing age five whose deaths five could avoided mean conditions like heart disease cancer treatment diabetes rise countries better nutrition diseases require treatment many years yet deaths nurses midwives nurses midwives noncommunicable diseases already account could prevented nearly twothirds global deaths developing existing expected increase vaccines world people living stigma discrimination hiv discrimination stigma prevent patients million received suffering diseases hiv even antiretroviral therapy asthma accessing treatment figures based world health statistics mortality rate per live births world bank hunger vital statistics resource density physicians total number per population except stated global report unaids report global aids epidemic speakers global issues un latest available year global health observatorygsk corporate responsibility report innovative science create value biggest contribution developing global portfolio meet key innovations case study health needs people around world make improving focusing products provide investigational health scientific greatest value patients healthcare payers medicines development including joining forces innovation research providers targeting cancer diabetes heart disease battle four candidate vaccines development new treatments substantial investment pipeline expect deliver phase iii data antimicrobial resistance vaccines consumer research development rd assets end collaboration public private partners potential launch new products gsk one five pharmaceutical healthcare products strong commitment open innovation next three years biotechnology companies involved gsk also advocates public policies support pioneering publicprivate collaboration scientific innovation broadly product launches included potiga tackle rise infections partialonset seizures people epilepsy mrsa resistant antibiotics meeting health needs worlds poorest votrient softtissue sarcoma rare people one key research objectives aggressive form cancer usa million million committed finding newer avamys allergic rhinitis china newdrugsbadbugs programme launched better medicines vaccines patients also received approval europe support innovative medicines initiative aims stimulate developing countries poorer populations nimenrix vaccine invasive research discover new antibiotics middleincome countries meningococcal disease usa part european commissions fluarix quadrivalent new influenza vaccine action plan rising threat menhibrix combines vaccines antimicrobial resistance haemophilus influenzae type b modern medicine dependent effective meningococcal groups c consumer antibiotics bacterial infections healthcare division also launched new becoming increasingly resistant existing products abreva conceal treatments pipeline new skin health category new variants antibiotics described ribena tailored africa market see world health organization virtually dry annual report information gsk brings wealth expertise pipeline product launches programme gained years experience developing antibiotics bn size fund stimulate research discover new antibiotics use term developing countries include leastdeveloped countries identified un currently rd investment countries subsaharan africa noneu lowincome information read position statement middleincome countries defined world bankgsk corporate responsibility report innovative science create value continued innovate create smaller research teams access catalyse innovation case study closer science specialist collaborations public rigorous process involved developing multidisciplinary discovery performance private organisations promising idea product approved units dpus reducing calorie patient use take years costeffective possible including sugar content drinks many ideas research make invest best scientific opportunities identifying projects likely unsuccessful far see website new medicines example translating terminating investment earlier research development process recent discoveries pattern recognition stage free resources pursue part commitment help receptor biology new treatment promising leads consumers make healthier choices people working rd autoimmune diseases signed partner uk dedicated finding new treatments transforming approach governments public health responsibility offer greatest benefits research treatments offer speeding rd process making deal ribena lucozade drinks patients around world help significant improvements existing new medicines available patients sooner ranges already include lower calorie effectively options new treatments chronic options lucozade sport lite obstructive pulmonary disease based see annual report details working reduce sugar improved understanding patient needs calorie content without compromising performance nutrition committed cut sugar content readytodrink case study ribena products uk ireland reduce calorie sugar content lucozade energy range speeding innovation benefits melanoma patients uk ireland levels rd organisation working diagnostic test identify tumours also using scientific expertise hard reduce time takes get new carrying mutation focused develop innovative products medicines market resources conducting trials ribena plus vitamins c submitted two new medicines regulatory efficiently possible support immune system ribena plus authorities less seven years rapid development two calcium healthy bones identified potential cancer treatments new agents particularly important lucozade revive calories early development programme metastatic melanoma patients b vitamins improve energy levels became clear dabrafenib ongoing phase iii trials combination braf inhibitor trametinib therapy dabrafenib trametinib mek inhibitor clinical activity different melanoma treatment metastatic melanoma tumours settings investigating genetic mutation collaborated compounds tumour types biomrieux develop robust genetic mutationgsk corporate responsibility report innovative science create value continued focus patient collaboration others case study case study guide research essential accelerate discovery new medicines us understand patients need vaccines make collaboration part supporting scientific catalysing innovation focus patient programme business model collaboration new bioscience hub brings patients gsk sites speak directly entered approximately latin america africa rd teams healthcare research collaborations external saw first businesses move needs helps us make better medicines public private organisations new stevenage bioscience catalyst sbc inspires employees trust science programme latin discovery partnerships academia research park joint venture help improve patients lives hosted america gathered momentum seven patient insight seminars sites programme example partner partnering gsk teams scientists department business innovation eight academic institutions worldwide develop medicines diseases affecting skills gsk wellcome trust east theme strengthening develop innovative research region plan extend england development agency patient voice gsk brought new medicines unmet health needs programme african countries technology strategy board aims foster together people including collaborative scientific community drive established programme already investment gsk employees healthcare professionals innovation bioscience nine projects underway europe patients patient advocacy group trust science active projects north america diseases targeted include located next gsks site stevenage uk representatives discuss range brazil seven argentina areas huntingtons disease neurodegenerative million facility offers small biotech topics including preterm labour rheumatoid tropical neglected metabolic genetic disorder severe pancreatitis life sciences companies startups arthritis asthma parkinsons disease systemic respiratory diseases gsk invests around lead multiple organ failure death academic institutions access expertise sclerosis melanoma alzheimers disease million year trust science networks scientific facilities associated provide recordings seminars projects external partners contributions partner institutions multinational pharmaceutical companies dedicated area intranet enabling developing vaccines treatments target including brazilian council science provides largescale technical equipment technology foundation employees learn benefit neglected tropical diseases see laboratories four research support state paulo discussions diseases developing world scientists housed buildings designed ministry science argentina malaria polio see minimise environmental impacts increase funds available million announced plans aeras global tb addition number companies already new research annually vaccine foundation run multicentre located sbc also set become proofofconcept clinical trial test addition gsk first pharmaceutical centre innovation cambridge university mase vaccine candidate tb company participate brazilian healthy adults years age governments science without borders also working international programme enabling phd scientists aids vaccine initiative research vaccine work discovery performance units hiv longterm projects gsk laboratories us uk spain seven brazilian scientists worked us gsk corporate responsibility report innovative science create value continued open innovation many existing treatments tb gsk remains committed sharing information case study yearsold clinical trials encourage innovation targeting diseases need taken six months people often clinical study register developing world fail complete course hope announced plans enable researchers exploring new potential commercial return sharing data speed development access detailed anonymised patientlevel treatments malaria developed countries changed essential new fasteracting treatments data sit behind results tres cantos way think intellectual property disease causes around million clinical trials scientific knowledge way work others deaths globally every year see behaviour open lab provided us open innovation strategy designed first time pharmaceutical company several significant advantages promote change beyond gsk sharing made public proprietary compounds development potential antimalarial supporting researchers open lab expertise resources intellectual property demonstrate signs activity tb agents important knowhow external researchers follows publication data twentytwo visiting scientists around use worldclass facilities financial scientific community although compounds could world made use facilities support access broad range current focus diseases inhibit malaria shared directly open laboratory tres cantos spain since pharmaceutical drug discovery expertise developing world already adapting research institutions around world launch projects opportunity collaborate open innovation models apply approximately compounds open lab portfolio four complete ten active open manner due unique areas great medical need scientific included malaria box created six approved start research environment open lab challenge including infectious rare research partner medicines malaria venture projects supported notforprofit challenging ambitious project diseases alzheimers malaria box set compounds tres cantos open lab foundation set undertaken given million funding gsk committed greatest chance success sharing research findings antimalarial activity shared million foundation research groups around world says matthew mcconville postdoctoral screened gsks entire doubling funding independent research researcher liverpool university pharmaceutical compound library also contribute information foundation overseen board using one chemical series two million compounds compounds searchable public database leading scientists supports researchers malaria compounds may inhibit tuberculosis tb bacteria available resources research neglected developing new medicines treat diseases published explore potential identified promising hits tropical diseases tuberculosis malaria developing world september new class malaria treatments could act starting points discovery set wipo research collaboration new medicines tb information private public sector organisations launched call proposals projects tres cantos open lab foundation compounds made available gsk founding member explore potential treatments tb malaria providing grant fund chagas disease leishmaniasis sleeping research liverpool university january programme shared sickness bill melinda gates new treatments malaria information insights centre foundation also launched two grand open lab facility spain world health medicine work challenges seeking new research ideas metap inhibitors tuberculosis saving malaria opportunity come centre estimated scientist spend time open lab three months work point knowledge pool formed rolled malaria compounds published wipo researchgsk corporate responsibility report access healthcare aim significantly adapt range sustainable business affordability case study models tailor approach reflect improve access gsk st needs countries different markets lack innovative business models flexible products people access healthcare acute gsk tops pricing help people get vaccines need around world worlds poorest countries developing access medicine index medicines need building countries market access dcma business particularly emerging markets developing appropriate operating unit clear objective increase increasing overall volume products gsk topped access medicines index product range providing patient access gsk medicines vaccines atmi third consecutive sell commitment sustainable vaccines medicines around million people time ranking access pricing includes countries expanding market medicines foundation examines flexible pricing based countrys affordable prices developing presence ensuring business much top pharmaceutical companies wealth ability pay defined countries investing continues sustainable strong improve access medicines world bank unit works country managers gsks developing world see quote stronger healthcare systems businesses provide holistic integrated index founder wim leereveld tiered pricing vaccines linked gross approach increasing access reflects national incomes per capita volume orders needs country since dcma score five ranked unit established volume highest overall achieved highest capped prices patented medicines medicines supply leastdeveloped score four seven categories vaccines worlds poorest countries countries increased nearly access management research products sold leastdeveloped countries million units development capacity advancement ldcs price million philanthropy top three uk categories developed countries work closely affordability partnerships including discount governments healthcare providers payers atmi report noted gsk invests cards reimbursement schemes payment healthcare systems understand money company plans patients middleincome countries needs help ensure products targeting diseases covered index available affordable highlighted partnership help uninsured patients developed pathmalaria vaccine initiative mvi countries governments facing develop rtss malaria vaccine austerity measures see also recommended gsk also encourages governments adopt increase transparency public policies support differential pricing marketing campaigns drug recalls example continued support eus tiered pricing regulation work uks industry government forum access medicinesgsk corporate responsibility report access healthcare continued commitment extends treatments benign prostatic hypertrophy fraxiparine partnering gavi gsk also leading supplier vaccines noncommunicable diseases ncds anticoagulant ultiva anaesthetic arixtra longstanding partner others cervarix protecting women cancer cardiovascular disease mental health venousthromboembolism vte zeffix gavi alliance funds immunisation cervical cancer affordable prices chronic respiratory diseases hepatitis b vaccines capped programmes worlds poorest pan american health organization growing fast middle lowincome west european average price countries prices gavieligible countries purchases behalf middleincome countries information also reduced prices little one tenth developing countries latin america approach ncds read lengthy treatment offpatent antibiotics augmentin zinnat developed countries caribbean regimens conditions certain countries vaccines expensive exploring ways increase gavi launched worlds largest case study sold small private market ldcs affordability introducing smaller pack sizes mass vaccination programme offered western european see case study researching dose pneumococcal disease pakistan using gsks average gavi alliance unicef extending immunisation requirements ways combine drugs synflorix vaccine pneumococcal disease purchase large volumes vaccines patients need two separate medications leading cause death children lifethreatening worlds poorest children always benefit also introducing risksharing models lowest prices measure impact five developing countries programme rotavirus several markets example brazil eight price reductions sales volumes pakistan children die million people access tykerb since increased significantly reaching pneumococcal diseases year expected offering secure supply rotarix successful introduction risksharing patients sales medicines protect million children year vaccine low cost helping scheme involves breast cancer increased markets pneumococcal vaccines expected reach gavi alliance immunise million children patients using tykerb assessed cut product prices increase access gavisupported countries rotavirus rotavirus weeks responded flexible pricing vaccines synflorix introduced madagascar severe diarrhoea causes kills half million treatment reimburse cost available kenya ethiopia children year one child every minute vaccines included immunisation price caps leastdeveloped previous year provide synflorix gavi responsible millions campaigns countries worldwide hospitalisations clinic visits year countries ldcs discount innovative financing delivered billion million vaccines could reduce suffering worlds ldcs offer gskpatented vaccine doses use mechanism known advance market deaths rotavirus causes products heavily reduced prices prices developing countries commitment gsk provide minimum capped price million doses synflorix gavi help gsk committed supply gavi supported expansion life uk france products sold expand immunisation programmes alliance rotarix saving immunisation programmes nearly uk provided price covers pneumococcal disease developing countries vaccine purchased high years offering vaccines manufacturing costs offer protecting million children volumes long time period reduced cost developing countries using sustained longterm able reduce price us per tiered pricing system based gross national also supplying gavi rotarix dose gavi alliance aims expand capped prices apply following brands incomes defined world bank vaccine rotavirus another leading cause rotavirus vaccinations countries seretide asthma chronic obstructive pulmonary also able significantly reduce childhood mortality see case study together worldwide six gavieligible disease copd avamys rhinitis flixotide price per dose selling vaccines rotarix synflorix agreements gavi countries introduced rotarix asthma malarone malaria avodart demand relatively predictable immunise million children national immunisation programmes large volumes longerterm contracts making significant contribution armenia ghana malawi moldova un millennium development goal reduce tanzania yemen applies individual product lines formulations sole supplier market child mortality twothirdsgsk corporate responsibility report access healthcare continued flexible pricing payment plans pricing according patient income equivalent efficacy comparator product case study middleincome countries example cancer patients hong kong france partnered economic apply discount depending committee enabling faster patient access gsks flexible pricing approach innovative income levels eligible patients epilepsy treatment trobalt using pay smaller pack size payment schemes middleincome countries enabling people access assessed specialist ngo pay performance risksharing model makes asthma medicine healthcare provider full reimburse cost treatment products helping us increase volumes affordable reimbursed ngo turn stopped within first four months sell growing markets example reimbursed gsk since scheme also offer conditional flexible pricing sales volumes avodart treatment worldwide million people introduced tykerb patients structure based results postregistration enlarged prostate avamys nasal spray affected asthma disease benefited expanded studies comparative trials allergic rhinitis grew accounts deaths year include votrient revolade patients respectively emerging markets patient assistance programmes us many patients oral medications benefiting votrient revolade asia pacific market access pricing first treatment option however several programmes help uninsured treatment increased team helps local operating companies provide slower relief may underinsured patients us get respectively since introduction establish appropriate pricing market produce systemic side effects medicines need eligible patients patient access scheme expensive inhaled versions countries average national extended cover benlysta lupus patients enrolled us patient assistance programs medications income level warrant list price prescribed gsk medicines reduction affordability remains barrier payment plans enable patients vaccines worth total million december launched many patients offer range payment manage cost treatments million ventolin rotahalerrotacap indonesia schemes enable patients afford monthly repayments interest lowcost inhaler uses single dose programmes include treatments need easily often possible example repayment scheme capsules salbutamol bronchodilator partnering ngos include enabled patients peru commitment access cancer sold small packs patients brazil access prolia osteoporosis specialty treatments buy needed aim bring discount cards enable eligible patients product millions patients helping governments manage bridges access nonspecialty medicines senior citizens disabled people markets emerging markets gsk vaccines access program healthcare costs europe lowincome patients chronic diseases asia pacific within next five years gsk access senior disabled patients receive direct discounts picking public healthcare budgets immense enrolled medicare part prescriptions partner pharmacies pressure many european countries result ukraine offered asthma patients economic environment tailor addition programmes uninsured discount card seretide four approach needs specific countries medicare part patients copay years approved votrient work closely governments achieve assistance programmes help patients metastatic renal cell cancer best results demonstrate value patients satisfy income eligibility requirements access payers healthcare professionals taxpayers expensive oncology immunology industry medicines also participate discount savings card programme together rx access uk example committed patients without prescription drug coverage markets benefit refund part national health services see information viiv healthcares lowcost inhaler expenditure votrient failed show next five years us patient assistance programs hivaidsgsk corporate responsibility report access healthcare continued availability products portfolio expansion case study case study product registration access medicines dependent already sell medicines vaccines affordability also availability right partnering improving health leastdeveloped countries medicines available right places vodafone mobile health committed making new medicines nutrition rural india patients benefit rd pipeline widely available work improve availability medicines december announced new developing countries well engaging seventy per cent population increasing product registration new strategic partnership vodafone regulators enable registrations india live rural communities often existing products across markets seeking use mobile technology help vaccinate medicines existing portfolio limited access medicines health advice strategic alliances acquisitions children common infectious anticipate next years services poor nutrition frequently expanding presence african diseases africa proliferation mobile include treatments infectious exacerbates health problems areas countries partnerships ngos phones africa offers opportunity diseases noncommunicable diseases particularly mothers children un organisations example create innovative costeffective ways asthma depression cardiovascular many half children living overcome barriers vaccination rural areas india malnourished support objectives un commission disease cancer account lifesaving commodities women initial focus new partnership deaths globally pharmaceuticals consumer children oneyear pilot project mozambique healthcare businesses india joined begun extensive catchup establish mobile technology could forces promote better health programme product registrations bring increase proportion children nutrition areas building established products developing vaccinated encouraging mothers take strong reputation horlicks brand countries particularly subsaharan africa vaccination services supporting health teams offer advice support received approvals products workers improving record keeping community organisations local developing countries therapy areas enabling better management vaccine doctors pharmacies mobile health central nervous system noncommunicable stock successful project create vans deworming health camps model replicated throughout diseases respiratory antibiotics oncology also working local healthcare mozambique scaled across africa also shifting approach providers increase access medicines launch new products pipeline zentel worm infestations offering affordable options new drugs fesovit iron deficiency treat diseases first enter market worsen blight malnutrition launched benlysta treatment systematic lupus erythematosus hong kong simultaneously offered measures increase affordabilitygsk corporate responsibility report access healthcare continued local manufacturing strengthening healthcare systems last ten years supported case study capability building work network education since gsk reinvested profits support immunisation nesi local manufacturing increases availability generated worlds leastdeveloped provision funding enable independent supporting franchised supports local economies cut costs production transport products countries ldcs community programmes vaccinology training healthcare workers local medical clinics strengthen healthcare infrastructure subsaharan africa north africa savings passed patients kenya rwanda countries primarily training middle east skilled knowledgeable form price reductions however community health workers human resources key delivering always appropriate strategy expanded partnership reinvestment community healthcare services population number joint ventures health workers trained basic healthcare nesi supports peopledevelopment w enit th e ro prn ise e f ta hm ai tl e xh te ea nl dth c c ep sr si v ta ot e technology transfer arrangements help delivery act first point contact initiatives nesi contributed healthcare rural slum areas build capabilities developing countries people remote marginalised improvement quality sustainable using franchise system enable local research manufacture vaccines communities nearest health clinic immunisation programmes provided nurses operate basic medical increasing market access include new could hours even days away deliver services low middleincome countries clinics known child family wellness joint ventures daiichi sankyo develop vaccinations diagnose illness administer capacity building education health posts providing access distribute prophylactic vaccines japan medicines provide pregnancy support training become key partner finance training support biological e leading indian vaccines company offer hygiene sanitation nutritional organisations unicef enable nurses create new health research development sixin advice improves health particularly gavi implement vaccination posts rwanda next three years one combination paediatric vaccine see women children reduces programmes region addition existing clinics longstanding partnership burden health system managing also help strengthen healthcare kenya already support half brazils oswaldo cruz foundation cases locally systems initiatives tackle million patients year gsk already covering polio haemophilus influenza type b committed partnership hib measles mumps rubella rotavirus invested based counterfeit medicines illegal establish initial posts rwanda pneumococcal disease see profits funding contribute dangerous provide million interest approach technology transfer training health workers free loan enable expansion see behaviour reach five million people next franchise network strengthen health infrastructure three years developing countries also partner harambe entrepreneur alliance fund reinvestment programme fellowship supports african entrepreneurs delivered partnership working innovative solutions micro three nongovernmental organisations health insurance mobile technology regional expertise work save healthcare harambe gsk fellowship children west africa amref east attracted highly qualified young southern africa care international african entrepreneurs since asia october programme empowered social business ventures place least developed nigeria rwanda zimbabwe south africa countries made profit gsk corporate responsibility report access healthcare continued reinvestment programmes established countries central african republic sudan afghanistan nepal south sudan bangladesh niger chad bangladesh niger myanmar trained community trained community health health workers established volunteers screen children laos community support groups signs illness malnutrition cambodia provide essential health promoted local health services services health education support people awareness support save children families rural mauritania northeast country care international mali senegal guinea burkina faso guinea strengthened capacity health yemen workers deliver maternal djibouth newborn child health services well family planning helping benin ethiopia tanzania uganda improve quality healthcare liberia uganda children age sierra leone togo rwanda provided elearning remote burundi professional development five save children nurses midwives working democratic republic tanzania congo rural areas amref angola mozambique zambia initiatives acknowledge sudan split haiti sudan south sudan developed delivered train running trainer courses help community madagascar p inr eg ar ca hm cm oue ns ry health workers bring lifesaving healthcare children living earthquakeaffected region see website leastdeveloped logne save children haiti lesotho full list programmes countries countrygsk corporate responsibility report diseases developing world neglected tropical diseases take holistic approach working commitment progress date polio malaria partners research new vaccines played leading role partnership donated three billionth treatments see make existing industry gates foundation albendazole tablet fight lf blight worlds ones available affordable see resulted london declaration intestinal worm infection lf leading vulnerable communities well strengthening healthcare systems commitment pharmaceutical companies global cause disability intestinal worms see governments nongovernmental organisations infect millions children around world aim help control causing chronic infections result also advocate adoption public control eliminate neglected eliminate malnutrition impair development policies provide adequate financing tropical diseases end decade diseases transform mechanisms gavi alliance together london declaration partners support help achieve world lives contribute funding immunisation poor countries committed eliminating lymphatic filariasis health organizations target deworm global fund fight aids tb lf known elephantiasis guinea worm school age children countries socioeconomic development malaria board gavi blinding trachoma sleeping sickness intestinal worms endemic donated million albendazole treatments tackle developing countries roll back malaria partnership also leprosy controlling soiltransmitted helminths lf soiltransmitted helminths founding member global alliance intestinal worms schistosomiasis river committed donate eliminate lf helped organise blindness chagas visceral leishmaniasis billion year since major conference neglected tropical collectively industry supply half billion people diseases world bank wilton park drugs needed first countries treated meeting malaria experts annual report london declaration antiparasitic tablet countries integration new tools achieve zero including scorecard showing status completed mass administration deaths elimination disease published january treatment neglected tropical diseases established dedicated ntds unit researching new treatments accelerate contribution neglected tropical diseases ntds threaten also investing research global effort tackling ntds billion worlds poorest people ntds partnerships often preventing working research funding partnerships organisations drugs neglected perpetuating cycle poverty yet initial focus working align efforts diseases initiative notforprofit product partners tackling five development partnership little invested preventing diseases treatments already exist lf treating began work partnership onchocerciasis schistosomiasis trachoma university dundee wellcome trust soiltransmitted helminth diseases develop effective affordable treatments intestinal worms three neglected tropical diseases chagas disease leishmaniasis human african trypanosomiasis sleeping sickness collectively responsible around deaths year across developing worldgsk corporate responsibility report diseases developing world continued also partnering us army polio produce supply ipv tiered prices case study brazilian ministry health countries implementing immunisation develop vaccine dengue lead eradication polio came step closer programmes working make potentially fatal dengue fever incidences removal india available lower cost combination vaccines vaccinations save dengue infection increased fold world health organizations list countries developing world contain ipv lives democratic last years approximately polio endemic three countries alongside vaccines diseases republic congo billion people globally risk afghanistan nigeria pakistan yet diphtheria tetanus whooping cough phase clinical trials dengue declared poliofree also investing around million gsk partnering unicef purified inactivated vaccine dpiv began long history supporting efforts new manufacturing facility wavre us programme vaccinate mothers puerto rico us collaboration eradicate polio early saw two key belgium produce vaccines containing ipv babies democratic republic us army sponsorship agreements support polio developed emerging markets congo drc one six also partfunding new london eradication developed first vaccine also launched new joint venture children die age five centre neglected tropical disease supplied oral polio biological e leading indian vaccines children drc risk research joint initiative imperial vaccine opv ever since provided company research development outbreaks preventable diseases college london london school million doses global polio sixinone combination paediatric vaccine polio measles hygiene tropical medicine eradication initiative publicprivate partnership vaccine would combine ipv immunised raising awareness natural history museum led national governments world biological es vaccine diphtheria tetanus among community leaders promoting undertake innovative research health organization committed whooping cough whole cell pertussis importance vaccinations well control mapping diagnosis meeting least initiatives polio hepatitis b haemophilus influenzae type providing refrigeration equipment needed common ntd infections vaccine requirements procured b approved would enable fewer injections store transport vaccines soiltransmitted helminths unicef approximately billion children supporting compliance schistosomiasis impact lives doses continue support immunisation also entered agreement million children vaccinated measles around third global population initiative every country world uk health protection agency million polio following first research centre declared polio free national institute biological standards recorded cases polio cases dedicated ntds opv relatively inexpensive control nibscs nonpathogenic polio cases recorded taken orally vaccine distributed genetically stable salkderived polio strains volunteers without need trained giving us opportunity research healthcare worker sterile injection equipment potentially develop lowercost manufacturing however countries polio platform ipv component paediatric eradicated opv live attenuated vaccine combination vaccines long term phased replaced technology could lead manufacturing inactivated polio vaccine ipv prevent component developing countries risk polio reemerging vaccine live birthsgsk corporate responsibility report diseases developing world continued malaria published results date confirm rtss promoting use existing measures case study help protect african children community investment malaria responsible malaria followup results provide african malaria partnership supports local deaths year mainly among children data provide insights developing ngo programmes promote use age five subsaharan africa vaccine candidates efficacy different malaria new treatments preventative measures bed nets half worlds population risk parasite transmission settings longterm indoor spraying control mosquitoes disease efficacy impact booster dose resistance current treatments grows atrisk communities researching vaccine results expected publicly developing new medicines treat available end malaria made antimalarial example funding threeyear researching vaccine programme amref southeast compounds available stimulate malaria years since vaccine approved remain tanzania already increased use research area malaria key working develop committed price cost production bed nets first focus tres cantos open lab vaccine publicprivate partnership plus small return around two years halved malaria deaths among see path malaria vaccine initiative reinvested research development underfives kenya partnership mvi aided grant bill second generation malaria vaccines vaccines partnership nonprofit save children distributed melinda gates foundation rtss malaria diseases developing world organisation medicines malaria insecticidetreated nets reached vaccine candidate final stages venture research addressing people two years clinical development pivotal phase iii two pressing needs treatments work family health international trial underway seven african countries drugresistant strains malaria ghana raised awareness need involving children parasite treatments species seek prompt treatment malaria malaria predominant asia latin america plasmodium vivax tafenoquine investigational medicine developing treatment relapse prevention plasmodium vivax malaria deaths year malariagsk corporate responsibility report health wellbeing communities fund support programmes include develop product financial donations giving breakdown type giving improve health infrastructure health local programmes hygiene sanitation education medicine gsk donated medicines valued leverage core consumer health product donations million cost million capabilities make humanitarian relief response science funds almost half total giving education develop healthcare professionals million product donations significant contribution future investments benefit used support lowincome patients health wellbeing communities bring value business patient assistance programs communities building relationships trust key usa see stakeholders strengthening reputation million product donations cash product inkind engaging employees delivered partners americares direct time aim increase impact relief international ima world health management partnering local organisations supporting map international project hope total programmes designed longterm humanitarian aid partners distributed sustainable impact encouraging donated medicines countries financial giving type programme employees get involved volunteering included providing supplies antibiotics supported basic medicines oral hygiene items see people affected conflicts cholera epidemic niger floods philippines hurricanes global community investment isaac sandy usa totalled million million compared million million continued invest phase personal hygiene sanitation education programme prevent diarrhoea pneumonia teaching children health wellbeing importance hand washing education began integrating oral health education programme reached million children countries since also provided million donations albendazole part commitment eliminate lymphatic filariasis see cashgiving supported programmes aimed strengthening healthcare infrastructure gsk values product donations cost goods believe part reinvestment truer reflection cost gsk wholesale acquisition cost value cost reported wholesalers used profits make leastdeveloped countries standard pharma industry valuing product donations community investment total value product donations based wholesale see acquisition cost milliongsk corporate responsibility report health wellbeing communities continued case study case study case study case study partnering improve strengthening empowering women rethinking health roma communities immunisation infrastructure latin america means healthy mumbai slums community usa working four different ngo support womens development partners improve access healthcare organisation pro mujer empowering estimated eight million people began convene series socially excluded roma communities women overcome poverty living slums mumbai india forums better understand barriers bulgaria hungary romania five latin american countries risk disease high third opportunities build healthier slovakia five million roma people next three years holistic package children fully vaccinated communities usa gsk partnered lack basic services clean drinking education healthcare financial first birthday partnered media company atlantic water sanitation healthcare services including loans start international ngo path mumbai host conversation community businesses established threeyear programme government local communitybased health three diverse american cities already trained health mediators organisation develop sustainable programme helps women gain access forums philadelphia st louis improve health awareness tackle integrated approach improving education training financial support denver brought together hundreds high rates infectious diseases child immunisation infrastructure increase including loans start small businesses community stakeholders experts mortality among roma communities support vaccination levels proportion profits local health organisations government ranges medicines vaccines reinvested families worked five health posts serving businesses academia discuss regular health checks health education health programme helped children one year old work together effectively help family counselling far nearly educate empower build selfesteem raise awareness importance people live healthier lives insights gained children benefited women improved health vaccination provide coldchain storage discussions help shape roma settlements also working financial independence lift delivery vaccines use mobile approach local engagement eu government develop new policies families technology record data send text usa hope help influence support secure longterm funding poverty message appointment reminders local policy decision making health mediators roma communities parents end month project half children fully immunised project created blueprint immunisation programmes similar settings around world children one year old reached support five health postsgsk corporate responsibility report health wellbeing communities continued case study case study case study read online helping sick children improving dental supporting migrant go home uk hygiene southern africa communities publish detail online key issues including shanghai china clinical trials developing world helping ukbased charity aquafresh dental hygiene programme wellchild help seriously ill children teaching children southern africa developing world vaccine production new citizen health care project technology transfer families providing funding brush teeth fund helping migrant communities ip access medicines three nurses provide specialist care working clinics community shanghai china access healthcare developing countries support enabling children leave groups focus raising mothers education nearly million migrants make pandemic preparedness hospital cared home awareness improved oral hygiene population city developing countries gskfunded nurses look effectively reach whole family many residents technology transfer capacity building children longterm illnesses aquafreshs range colourful toothpastes permit hukou making difficult developing countries well providing valuable emotional toothbrushes also encourages children access basic services working together health support families mothers children brush regularly partnered xintu centre pricing reimbursement raise awareness wellchilds life awareness programme community health promotion local ngo changing work ran promotional gsk briefing noncommunicable already reached children specialising public health education diseases developing world campaign packs ribena botswana mozambique namibia establish four community centres gsk position statement post sponsored wellchild awards zambia zimbabwe childrens playrooms classrooms development agenda celebrate bravery seriously lecture rooms provide health education product donations ill children young people uk services migrant dedication health professionals communities care project financial times citi ingenuity award urban ideas action planning open another centre beijing children reached migrants shanghaigsk corporate responsibility report hivaids viiv healthcare global researching new treatments transmission hivtb coinfection total countries leastdeveloped countries end clinical trials subsaharan africa countries total specialist hiv company viiv healthcare made significant underway trials paediatric lowincome leastdeveloped countries established gsk investments research support pipeline studies african countries participating subsaharan africa home people pfizer joined new antiretroviral medicines paediatric studies include malawi south africa living hiv around world viiv provide benefits existing medicines tanzania uganda zambia zimbabwe shionogi focused efficacy side effects resistance profiles healthcare offers complete antiretroviral recognising urgent need address gaps arv portfolio notforprofit prices delivering advances december viiv healthcare submitted care treatment paediatric hiv viiv countries royaltyfree voluntary regulatory applications eu us treatment care people healthcare expanded commitment licensing policy viiv healthcare enables canada dolutegravir investigational living hiv broad integrase inhibitor treatment hiv area paediatric innovation manufacturers generic medicines sell seed fund includes firstofitskind public versions entire arv portfolio portfolio ten antiretroviral currently six clinical phase assets private partnership clinton health commitment covers marketed medicines medicines industry viiv healthcare portfolio well several access initiative chai mylan laboratories medicines pipeline licensed preclinical discovery programmes limited submit registration new viiv healthcare granted three additional leading pipeline partnership hiv discovery tastemasked dispersible abacavirlamivudine voluntary licences bringing total number performance unit include early work formulation paediatric use resource recent voluntary identifying new therapeutic options limited settings educational grants totalling licence granted medicines patent pool antiretroviral drug candidates novel approximately million also awarded foundation manufacture supply mechanisms action disease modifying five organisations improve paediatric hiv paediatric formulations abacavir therapies curative medicines research care treatment access partners around million patients addition viiv healthcares research teams include international aids society justri developing world access low cost generic build new connections collaborations mater misericordiae university hospital versions arvs developed viiv healthcare commercial academic amfars treat asia programme mainly supplied licensees organisations improve scientific elizabeth glaser pediatric aids foundation viiv healthcare licensees supplied understanding hiv work towards improving access hiv treatment estimated billion arv tablets compared cure example viiv healthcare gsk million however signalled scientists members international million people living cr report key patent lamivudine aids societys towards hiv cure industry hiv need treatment receiving expired half way meaning collaborative group viiv healthcare antiretroviral arv therapy unaids companies able continue supply founding member collaboration world health organisation aims longer required licence viiv healthcare hivaids immunological therapy public increase number million means future years private partnership launched viiv healthcare committed playing reporting volume sales viivs former viiv healthcare also supports collaborative part increasing access hiv treatment licensees viiv healthcare remains committed addition summary viiv healthcares research trials resourcepoor settings taking innovative responsible licensing strategy demonstrated contribution community response understand public health issues sustainable approach programmes cover agreement signed february hivaids information available online wwwviivhealthcarecom prevention mothertochild hiv middleincome countries lowincome medicines patent poolgsk corporate responsibility report hivaids continued middleincome countries viiv healthcare supporting communities case study adopts flexible pricing policy varies affected hiv according gdp burden hiv epidemic individual countries partnerships viiv healthcare funds community projects improving early infant diagnosis treatment africa incountry companies manufacture support people living hiv medicines locally also established global positive action programme june viiv healthcare malawi percentage hivpositive reduce cost treatment st year positive action aims build elizabeth glaser pediatric aids foundation infants months old initiated build local manufacturing capabilities capacity communitybased organisations egpaf began partnering twoyear art grew baseline partnership binnopharm russian enable grassroots community action project lesotho malawi swaziland august largely pharmaceutical company enables local address stigma discrimination since improve early infant diagnosis due improved caregiver followup secondary manufacture viiv healthcares positive action children fund pacf treatment eidt services expanding staff ancillary staff trained support medicines people living hiv russia awarded total million local capacities strengthening infrastructures viiv healthcare one example projects aimed improving health project supported efforts strengthen lesotho introduction integrated wellbeing women children families national health systems long term prevention mothertochild transmission usa viiv healthcares patient affected hiv viiv healthcare ministry health moh pmtct paediatric care treatment assistance programme helps uninsured country integrally involved committed million fund services ensured hivpositive lowincome patients access hiv medicines project rollout continuity assuring projects countries includes mother infant could continue patient savings card programme continued sustainability minimal renewed support grassroots community receiving care nurse provides savings eligible patients external support project sites projects making tangible difference throughout pmtct cascade outofpocket prescription costs countries altogether positive action project sites showing result percentage hivpositive start rate reimbursement pacf community grants disbursed encouraging increases early infant diagnosis infants initiated art climbed increased per viiv healthcares local operating rates treatment uptake nearly helped moh medication per month viiv healthcare also companies gave support hiv infants tested critical identify infected children previously lost supports welvista nonprofit programme community organisations find age eight weeks old referral distant art services facilitates access hiv medications wwwviivhealthcareeffectcom infants tested positive hiv swaziland paediatric hiv training nearly people waiting list initiated antiretroviral therapy art curriculum developed support us governments aids drug viiv healthcare integrated assistance program existing moh nurse training ensuring sustainability government ownership also result project advocacy moh swaziland nurses code practice amended allow nurses initiate art nationwide improving patient access art bringing art services closer populations needgsk corporate responsibility report behaviour focus researchers able access detailed anonymised patientlevel data clinical trials read section overview ethical standards principles sales marketing working healthcare professionals research practices manufacturing supply chain public policy patient advocacy approach tax gsk corporate responsibility report behaviour focus access patientlevel data clinical trials deliver success valuable researchers want opening learn existing medicines improve important achieve patient care number years gsk access responded external requests patientlevel put interests patients data casebycase basis going forward trial data allow researchers request anonymised consumers first driven patientlevel data published clinical trials approved terminated medicines values transparency respect integrity enable researchers examine trial data closely combine data patientfocus everything different studies conduct research takes commitment openness transparency clinical trials one step already publish summary results values backed clear code conduct robust compliance whether perceived positive systems training support help employees make negative every research trial gsk clinical study register almost right decisions standards extend suppliers contractors clinical trial result summaries available site receives average many ethical issues associated research almost visitors month early development rd manufacture sale products outlined plans add clinical relationships healthcare professionals patients regulators new plans acknowledge study reports onto register future need honest transparent address commitment individuals participate research trials putting information public domain people individuals participate hope might bring advances healthcare new plans acknowledge see operate research trials commitment reflect desire ensure contribution lead open challenge discussion afraid change health gains safeguarding work reflect societys expectations confidentiality ensure data used valid scientific reasons independent panel review request allowing access researchers able submit requests via dedicated website approved information provided via secure environmentgsk corporate responsibility report overview glance ethical standards principles commissioned independent commitments external perspective review drug safety processes revised simplified code conduct detecting adverse events c ontinue drive valuesbased approach make easier employees understand across life cycle product sales marketing practices across apply gsk values behaviours world interests consumers andrew witty gave keynote see patients core see speech annual pears business manufacturing supply chain continue ensure interests schools partnership lecture safety patients consumers gave us valuable insight established human rights steering group paramount importance way senior managers oversee approach design undertake clinical trials means responsible product quality assurance leader world intense connectivity applying un guiding principles business human rights monitoring reporting adverse events enforced transparency asked ongoing product usage us position authority see rigorously challenge need animal going power studies work minimise impact youve handed entrusted animal welfare investing driving message throughout development alternative studies organisation like gsk undoubtedly sales marketing sharing animalbased data challenging essential create reached settlement us address un guiding principles truly valuesbased business government resolve longstanding added anticounterfeiting technology human rights business across legal issues around sales products china resulting significant operations supplier relationships marketing practices reduction number reports fake transparent possible see gsk medicines reaching market clinical trial data including publishing clinical study reports without patientlevel see data outcome trials medicines conducted gsk within appropriate research practices process making available researchers public policy patient advocacy access anonymised patientlevel data committed provide access anonymised scientific enquiry trial data published clinical trials published list memberships trade authorised terminated medicines associations primarily represent demonstrate gsk interactions addition disclosing results pharmaceutical consumer product patient advocacy groups political research publicly accessible clinical vaccine businesses national regional stakeholders conducted appropriately study register website receives international levels ethically transparently professor david grayson average almost visitors month director doughty centre corporate responsibility see cranfield school management see httpwwwsomcranfieldacuksompresearch researchcentresdoughtycentrehomegsk corporate responsibility report ethical standards principles ethical conduct priority revised simplified code living values scientific engagement conduct make easier employees gsk failure uphold understand apply gsk values focusing integrating valuesbased scientific engagement policy established high ethical standards behaviours number key principles culture within gsk employee survey explains principles erode trust company previously covered policies results reflect efforts engage external scientific activities integrated code available integrate valuesbased culture gsk advisory boards publications scientific products damage languages supported new respondents stated understand congresses medical education reinforces reputation result online policy resource centre provides constitutes ethical business practices clear distinction scientific information support training employees conduct job promotional activity gsk ensures serious financial related topics revised code also annual business ethics certification scientific activities carried way legal consequences publicly available website managers confirm compliance reflects values established internal quality assurance group monitor gsk employees access whistleblowing code conduct revised implementation practices mechanisms use get advice relaunched report suspected cases misconduct managers asked undertake bribery corruption anonymously required training new approach help zerotolerance approach bribery reinforce role leaders inspire corruption set preventing right behaviour create safe environment corrupt practices policy antibribery employees speak key leadership corruption programme reviewed development programmes updated audit risk committee annual basis reflect principles living gsk values performance reviewed anti every day decision making bribery corruption oversight committee medical governance meets monthly team help implement policies system principles policies accountabilities known medical governance designed make sure research activities conducted recognised standards line values responsibility medical governance sits chief medical officer organisationgsk corporate responsibility report ethical standards principles continued human rights management human rights embedded privacy bcrs comprise various elements business including including internal corporate policies committed upholding un data protection security continues standards training programmes audits universal declaration human rights employment standards covering topics high priority us global privacy global privacy office developed oecd guidelines multinational enterprises diversity equal opportunities health principles ensure personal data rolled robust privacy awareness core labour standards set safety see collected used processed transferred training programme includes international labour organisation ilo supplier standards audits help us stored appropriately securely line training modules global privacy gsk signatory un global compact promote human rights supply chain legal requirements committed principles bcr standards voluntary global standard human rights see exercising highest standards integrity labour environment anticorruption dealing protecting personal data audit assurance group systems protect rights people taking require employees suppliers performed independent audits support guiding principles business part clinical trials see comply global privacy principles compliance privacy policies human rights endorsed united efforts improve access healthcare global privacy office oversees privacy standards well applicable laws nations human rights council help promote right health processes communicates best practices addition implementing data reviewing policies processes see throughout gsk privacy monitoring programmes make sure reflect principles business unit across enterprise global established human rights steering read online human rights statement awaiting approval uk privacy office identified key privacy group senior managers oversee information commissioners office controls included monitoring approach steering group includes activities embargoed countries binding corporate rules bcrs submission programs ensure consistency data representatives functions human continued implement collected monitoring activities stakeholders concerned resources procurement chaired critical elements bcrs required uk given global privacy office analysis business activity countries targeted senior vice president governance european data protection regulations trending determine whether internal sanctions laws cuba north korea ethics assurance transfer personal data affiliates located controls effective iran sudan syria share uns belief plan place address gaps identified outside european economic area people denied access review approved fully implemented bcrs medicines regime operating improve efficiency transfers country aim provide medicines personal data within company vaccines countries need increase confidence security wish purchase observing personal data entrusted applicable sanctions export controls scope bcrs cover personal data comply disclosure requirements held employees research subjects iran threat reduction syria human healthcare professionals partner rights act researchgsk corporate responsibility report ethical standards principles continued compliance addressing misconduct maintain build strong track record breaches external codes compliance additionally continued managers must ensure compliance contacts focus manufacturing quality seen collect information breaches external company policies areas responsibility made ethics increase disciplinary numbers industry government promotional codes corporate ethics compliance compliance channels mixture allegations good manufacturing practicegood commercial businesses found department investigates suspected legal misconduct requests information distribution practice gmpgdp category breach external codes times ethical policy violations guidance time period categories compared times employees report concerns suspected remained broadly consistent time investigate every breach external code take steps prevent reoccurrence cases misconduct variety employees employees remain company may include retraining corrective channels including confidential speak disciplined policy violations following policy violation receive retraining action including disciplinary action integrity line available increased monitoring support different languages dismissed cases retraining extended employees standardise reporting channels agreed leave company voluntarily colleagues prevent making employees wherever based report known separations similar mistakes consistent way refresh disciplinary actions included awareness campaign encourage employees documented warnings types policy violations get help report concerns policy violations related fully investigate suspected breaches breaches sales marketing codes confidential manner take disciplinary resulted dismissals action including dismissal separations documented warnings appropriate serious violations policies reported audit risk committee believe increases seen board due increased focus attendance payroll category violations attendance payroll respectively attendance gmpgdp issues mainly reported code conduct manufacturing business marketing promotional activities policy violations implemented tighter controls ensure total violations gmpgdp relates good manufacturing practice good distribution practicegsk corporate responsibility report sales marketing goal drive values reflect commitment consistently reinforce codes policies issues question originated high standards launched new global training compliance procedures different era company based approach sales code practice promotion customer making sure way pay sales teams ignored learned marketing practices across interactions applies reinforces values several years usa world interests employees involved sales marketing settlement us government taken action levels well third parties acting behalf company enhanced improved consumers patients covers areas providing information agreed make payments procedures compliance marketing core applies fees service payments healthcare billion relating investigations selling based values sale consumer professionals samples hospitality grants usa longstanding legal issues around transparency respect integrity patient donations states marketing sales marketing practices condition focus necessary removed products promotional activities must conform high settlement entered corporate employees engaged misconduct marketing prescription ethical medical scientific standards integrity agreement cia office broadened ability claw back based valid scientific evidence comply inspector general oig us department remuneration senior management medicines vaccines applicable laws regulations health human services event misconduct healthcare professionals industry codes sales marketing build existing comprehensive hospitals governments employees trained compliance programmes revised code criminal plea related aspects employees third parties involved marketing paxil paediatric use sales marketing must also follow wellbutrin certain uses failure business areas commercial practice policies include information initiation marketing codes well global status certain avandia studies periodic scientific engagement principles annual reports submitted us food drug administration civil portion voluntarily also implemented settlement made new system evaluating compensating admission liability beyond admissions sales professionals usa work criminal plea paxil wellbutrin directly prescribing healthcare professionals resolved allegations three separate new system called patient first bases investigations one sales incentive compensation primarily sales marketing nine companys products competency customer evaluations second certain nominal pricing overall performance business rather alleged bundled sales arrangements number prescriptions generate third companys promotion currently exploring take submissions avandia learnings patient first programme view informing global approach sales incentivesgsk corporate responsibility report sales marketing continued implementing directtoconsumer marketing marketing children corporate integrity agreement prescription medicines guidelines advertising children date employees covered advertise prescription medicines prohibit advertising children cia completed total hours directly consumers usa local legally mandated minimum age training requirements gsk board new zealand directtoconsumer dtc inappropriate market directors vendors also advertising prescription medicines drinks products year olds unless trained gsk managers permitted markets product delivers appropriate nutritional completed additional compliance training benefit children country improved updated dtc advertising usa governed products marketed promote policies procedures established dtc communications policy based drinks products responsibly ensuring controls centre excellence enhance phrma guiding principles direct advertising sponsorships messaging monitoring business established consumer advertisements appropriate nutritional benefit risk mitigation plans prescription medicines dtc sports star sponsorship important brands marketed products advertising usa reviewed legal lucozade sport guidelines state regulatory medical specialists new reporting progress regularly people set appropriate dtc television advertisements submitted us government example used sponsorship us food drug administration independent audit appeal solely fda review comment prior completed implementation cias children age broadcast advertise erectile requirements work doesnt end dysfunction medicines television next steps continue raise awareness revised policies practices us pharmaceuticals business monitor compliance live receive notice violation values every day warning letter fda advertising promotiongsk corporate responsibility report working healthcare professionals doctors healthcare believe hcps healthcare read work uk march gsk organisations hcos work hcps global code healthcare companies start report professionals hcps fairly compensated services expertise practice promotion customer annually payments made hcps valuable partners gsk provide us however payments must interaction online previous year aggregate level providing us scientific excessive must never transparency cover payments made hcps advising inducement reward prescribing consulting services financial support medical expertise products clear standards aligned committed publishing sponsorship well grants donations insights patient care international regional codes practice payments make hcps hcos healthcare organisations appropriate country laws regulations believe partnership countries also planning publish govern payments help fundamental operate complex challenging task information hcp payments number safeguard risk need align systems across countries specific reporting progress medical science work hcps hcos number countries multiple currencies requirements introduced helps meet patient ways meet different regional country coming years continue reporting requirements public health needs conducting research hcps conduct clinical support work towards transparency introduced achieve introducing research behalf acting investigators countries industry associations new processes gather data effectively responsible overseeing study governments establish specific guidelines accurately across business expertise insight resources help us disclosure develop deliver new patient treatments last years started also continue work towards publishing publish information several countries advising consulting hcps provide global figures aggregate level hcp supported introduction locally agreed expertise insight gsk advisory panels payments including advising consulting government industry association standards example specific diseases identification financial support sponsorship grants symptoms diagnosis may also usa payments made hcps donations conducting research speak behalf products individual level speaking consulting ukbased company use uk disease therapy areas relevant us published since standard basis approach began disclosing payments made institutions reporting global figures financial support sponsorship may hcps acting lead investigators provided hcp help attend separately also publish information assisting clinical research studies local international meetings must community investment grants product q aligned reporting new scientific medical andor educational donations grants us government requirements support limited registration fees make patient advocacy organisations read online reasonable travel meals accommodation australia published aggregate grants donations may made payments made hcps hcos since response unsolicited requests actively supported adoption hcos support healthcare medical industry association standards scientific research receive service privilege benefit returngsk corporate responsibility report research practices patient safety priority aspects research raise ethical conducted clinical quality reviewed informed consent concerns including relating animal assurance assessments confirm documentation procedures paediatric stages research clinical research use emerging conduct trials reflects standards including studies review led us enhance new product goes technologies aim address procedures identifying variations relevant investigator sites conducting gsk sale open transparent practices regularly local laws simplify informed sponsored clinical trials representing around engaging academics scientists regulators consent language work disclose sites provide primary policymakers stakeholders data regulatory approval based transparency clinical research results clinical research clinical research gsk processes including data quality committed reporting results high ethical quality clinical trials healthy volunteers protocol development clinical clinical research evaluates medicines standards apply patients enable us assess investigational study reporting vaccines irrespective whether research development medicines potential evaluate outcomes perceived positive negative contract research organisations carrying medicine approved believe fundamental wherever takes place clinical trials behalf marketing conduct trials accordance advancement medical science helps good clinical practice gcp gsk local operating companies involved inform prescribers patients guidelines developed international clinical trial activities findings relating medicines conference harmonisation based five new drug application nda annual principles contained world medical reports reviewed prior submission association declaration helsinki posting results research us food drug administration ethical principles medical research publicly accessible clinical study register fda provide update status involving human subjects website receives average almost study completed progress visitors month end trial protocols reviewed ethics addition investigations conducted contained almost results committee independent gsk response suspected irregularities summaries posted since launched made members public medical investigator sites contract research organisations early announced plans professionals scientists ethics local operating companies fully expand register include clinical committee power reject stop investigate concerns issues identified study reports clinical trial take corrective action appropriate seeking publish research results full training auditing clinical research independent regulatory authorities also papers peer reviewed scientific journals employees must complete training performed inspections gsk since made commitment gcp undertaking roles relating investigators use conduct clinical submitted articles publication gsksponsored clinical research trials october announced new gcprelated training activities commitment help researchers access represents successful anonymised patientlevel data completion elearning module clinical trials instructorled coursegsk corporate responsibility report research practices continued also along clinical trials developing countries one trials highlighted known oasis patient safety pharmaceutical companies collaborated clinical trials essential ensure investigated gsk product fondaparinux journal editors part medical innovative vaccines medicines arixtra preventing repeat heart attacks medicines potential risks well publishing insights practices initiative delivered treat diseases pneumonia set run study benefits although everyone takes identify steps improve credibility cancer diabetes important purchased study medicine arixtra medicine experience side effects industrysponsored research result vaccines medicines evaluated another pharmaceutical company important identify evaluate publication ten recommendations broad population countries study already underway given minimise safety concerns ensure overall closing credibility gap reporting used countries india patients enrolled receiving benefits medicine outweigh risks industrysponsored clinical research regulatory authorities require local trials medication took view trial safety effectiveness new medicines highlighting opportunities improvement run medicines licensed able continue must demonstrated clinical trials cm g aiml ls la n k p rn ei cy p sra u r la l f tc n sttt tuih pc ce e uls biee n ls ia n ca cr c ae nl ldua ql dr p ue un ea b sd g tl iit oc hc e v ae e nr ne e dd tw dt oo mt reh en ai sn ku e r e w dr ece avo yer g u l nonn opi tic e n bl gt en h ci aac sta u dl r n u et tr vn ri ea e ois sn pw g w eo dc hr l el cd n r aew n c hi bele et l r ca ha hn l ad ss le lw r en v ne gce ins g w gc wo oae n os r ce u cv c n li ite ndew u ice ca ad tn le pddh r ae w ac cfi e c trn ie crd edsi sn int tg agss nfi tf de ado r nt dh er rt n u ahti ten io e nt u au l yi ts wm r nb ae uhraf meo er k nr bee n eat n di r n p se g rw oo f ds p po ur ao om c ttd n eeu il nsypc bt b ss e e ic w ndia b gn e el te ue hb sce ai etd da ee dp b pep yf ff l le ae iv c cr g es ad e spa f p aro e nrr v dve ar ly matter world clinical one trial sites used study processes help us detect act trials take place safety wellbeing bhopal india site gas adverse events patients participating trials disaster gsk number one priority conduct intend run clinical studies bhopal global safety board makes decisions clinical trials high scientific site bhopal inspected product safety issues remit ensure ethical standards following strict indian regulator report concluded safety focus throughout product international regulations guidelines study generally well run according development review gsk products concerns raised international good clinical practice standards market board chaired conduct clinical trials india informed consent obtained chief medical officer composed senior concerns related gaining approval participants physicians scientists trials ensuring proper informed consent safety clinical trial participants improve patient safety systems providing compensation trial paramount importance us take created internal medicine risk participants appropriate concerns conduct clinical management advisory panel senior gsk trials seriously continue review staff act forum sharing information procedures ensure conduct best practice within company sponsored clinical research highest possible scientific ethical standardsgsk corporate responsibility report research practices continued pharmacovigilance external initiatives improve animal research case study pharmacovigilance relates understanding patient safety animal studies remain vital part reduction adverse effects medicines work government officials industry working partnership research many cases commissioned independent partners policy makers improve method used demonstrate accelerate standardise review drug safety processes safety systems medicines vaccines effects potential new medicine living clinical development confirmed gsks high standards detecting involved several body tested humans animal adverse events across life cycle product programmes including research also provide vital information gsk helped create new partnership also provided input development cardiac safety research consortium causes diseases speed development medicines pharmacovigilance regulations introduced collaboration industry regulators develop regulations require us test improving standardizing clinical european commission raise public academia improve cardiac safety new medicines animals development practices transcelerate confidence safety monitoring throughout drug device development evaluated clinical trials countries biopharm inc joint initiative among ten provided training gsk employees published several papers lead authors require additional animal testing even pharmaceutical companies focus regulations shared data led participated medicines approved use solutions enhance patient safety reduce several research projects elsewhere costs streamline clinical development protect partner european project ultimately gsk would like see benefits gsk involved five areas work managed european medicines research applied humans without transcelerate agency looks improve need animal testing developing industrywide standard pharmacovigilance techniques believe achieved foreseeable approach riskbased monitoring future animal research remains necessary clinical trials order enhance patient european programme pharmaco committed acting ethically safety ensure quality data vigilance pharmacoepidemiology providing animals health wellbeing launching shared portal investigators new venture helped establish involved trials streamline access provide training improve practices animal critical information pharmacovigilance students research welfare march introducing standardised good clinical healthcare professionals created office animal welfare ethics practice training qualification strategy oawes led chief investigators recognised veterinary medicine new office participating companies responsible developing reviewing partnering clinical data interchange policies overseeing humane standards consortium develop standards responsible use animals across gsk current support exchange clinical trial oawes initiatives look make animal data priority disease areas science modelling robust establishing reliable quick sourcing help provide better analysis data gathered quality comparator drugs use animal research increase clinical trials enhance patient safety use nonanimal research alternatives accelerate trial timelinesgsk corporate responsibility report research practices continued apply principles studies encourage rs culture regular performance percentage change animal use conducted external contractors training staff involved care use number animals used compared key drivers animal use behalf carried within animals raising awareness rs lower two main drivers gsk facilities past four years encouraging best practice recognise animal use rd investment vaccine animal quality assurance group assessed employees made significant sales increased period care welfare programmes advances implementing rs contractor supplier organisations animal welfare awards animal use declined compared vast majority either met yearonyear decrease since core principles animal welfare responded entered number partnerships reflects changing research priorities fewer recommendations improvements help reduce refine replace animal vaccines requiring testing animals animal care programmes occasion research including batch release continued focus decided work contractor signing agreement simulations plus rs initiatives animals used within gsk facilities animals used contractors behalf gsk either chosen adopt develop software simulates animals research including rd investment plus vaccine sales recommendations clear absorption drugs skin research carried contractors mice figures normalised first year data formation glaxosmithkline data includes animal research conducted external contractors following site visit humans animals could potentially number fish research models behalf data unavailable committed continuous improvement reduce experimentation increasing example zebrafish rs participating launch crack based screens evaluated assessing species used gsk animal research goal use animals initiatives organised national centre compound efficacy infectious scientifically necessary use replacement refinement diseases neurological therapy areas ott hh ee rr r odents scientifically feasible minimise pain reduction animals research nonrodents account rabbit distress scientists apply connect scientists different disciplines number animals used less og n human primates rs principles biomedical research encourage innovation rs animals use nonhuman primates ferret farm replacing animal research supporting association assessment bird methods possible accreditation laboratory animal care international advance standards reducing number animals used mouse animal welfare china organising two fish still providing information given conferences helping translate guide rat amount precision care use laboratory animals guinea pig refining techniques minimise pain pigs goats sheep distress maximise animal welfaregsk corporate responsibility report manufacturing supply chain effective responsibly year spend around billion supplier standards improve ethical labour health goods services suppliers safety environmental practices current managed supply countries third party code conduct defines collaboration initiatives include provision distribution system expect suppliers ethical conduct common preaudit questionnaires joint essential us get high ingredients materials buy antibribery practices labour practices shared audits helps reduce suppliers fed network protection human rights environmental duplication makes compliance quality products right gsk manufacturing sites health safety management interactions straightforward suppliers places right time countries manufacture nearly gsk employees new suppliers must accept products produce four billion comply principles code supply chain performance patients rely packages annually meet quality standards conducted environment health suppliers deliver value people working global business us procurement teams safety ehs audits existing manufacturing supply gms division engage existing suppliers raise awareness potential suppliers around best cost operating outsource terms code reinforce principles audits assessed suppliers asia responsible manner production costs manufacturing suppliers provide us finished riskbased approach determines extent supplier ehs audits partfinished product areas engagement supplier higherrisk existing potential suppliers need ensure high quality responsible suppliers identified based critical manufacturing products make supply chain risk americas pose patient business supply europe interrupted fail meet standards asia risks supply chain integrated africa overall risk management compliance total number oversight process audits significant suppliers conduct regional distribution total spend suppliers audits assess environmental health number types supplier audited ehs existing potential suppliers safety governance risk management significant gaps identified may type supplier americas europe asia total recommend use consultants support primary raw materials intermediates supplier making improvements suspend pharmaceutical ingredients restrict supply significant improvements contract made stop working supplier manufacturing decide work potential new supplier pharmaceutical formulations europe collaborating manufacturing consumer healthcare excipients actives us companies sector raw materials asia pacific pharmaceutical supply chain initiative psci africamiddle east aims improve security supply latin america japan reduce reputational risk helping suppliersgsk corporate responsibility report manufacturing supply chain continued conducted fewer ehs audits overall began map risks payment terms supplier diversity result revised audit supplier manufacturing sites help us better strategy prioritises suppliers plan potential interruptions supply changed standard payment terms small companies owned women critical business undertaken engaged property insurers fm global suppliers uk us people belong minority groups indepth audits suppliers often involving review risks supply continuity terms provide payments made within often represented supply multiple site visits including abovesite key suppliers suppliers first five days month follows chains large companies gsk believes governance risk management controls assessed expiry days receipt small diverse businesses significant believe approach contributing suppliers invoice potential meet procurement needs better relationships suppliers case study greatly value relationships bring value communities job significant sustainable improvements many suppliers understand creation revenue generation ehs audit findings suppliers years collaboration pressures cash flow financing sourcing diverse suppliers benefits occurred mainly emerging markets faced smaller companies time us helps us comply regulations included significant deficiencies design year connection divis uk willing review markets usa encourages operation safe plant equipment laboratories india celebrated new payment terms suppliers innovation exposes us poor management flammable liquids identify micro small new perspectives fresh ideas supplier inadequate fire prevention control medium size enterprises smes defined diversity programme led usa since signed first contract measures additional gaps identified european commission us support procurement teams divis supply ingredients zantac areas compliance regulations willing review new payment terms worldwide usa spend small drug used treat prevent ulcers management change emergency response suppliers falling within category diverse suppliers increased stomach intestines quality preparedness safe systems work loss ehs technical teams worked diversity suppliers defined relevant one key sponsors preventioncontinuity planning control closely divis managers develop legislation addition offer range participants msduk conference exposure chemical agents understanding requirements supply chain finance options supplier diversity london uk us suppliers total four suppliers critical findings support improved procurement teams large companies audits result one supplier quality environment safety systems suppliers changes made brought together ethnic stopped specific process causing divis strong focus putting profits payment terms little minority businesses listen presentations concern risk removed back community activities impact submit invoices towards network two others currently commercial villages near manufacturing facilities end month still pay agreements us one including building library paying suppliers faster customers several suppliers china teachers local schools pay us changes made make working bring robust procedures horticultural training local farmers payment terms suppliers consistent across group reduce complexity addition strategic audits past years divis grown also provide certainty suppliers strength companys audits contract manufacturers paid something business focused uk final products conducted ehs suppliers unanimously fed back us usa staff within business particularly india important ensure suitable standardsgsk corporate responsibility report manufacturing supply chain continued anticounterfeiting use technology must combined gsk anticounterfeiting activity strategies working customs decrease number counterfeiting poses serious threat authorities seize counterfeit products reported counterfeit incidents read online patient consumer health well provide customs officials information attributed combination business threat gsk products train identify effective preventative measures publish detail online key pharmaceutical companies counterfeits helped train serialisation programme china issues including work regulatory enforcement customs officials china malaysia also robust investigative enforcement gsk antibribery corruption handbook agencies address global problem vietnam took part regional training strategy led significant gsk antibribery corruption guidelines determined provide ways patients sessions organised world customs increase raid actions third parties check authenticity products organisation wco west east africa cloning technologies stem cell research disclosure clinical trial information example following pilot nigeria wco launched initiative called gsk anticounterfeiting activity care welfare treatment animals introduced anticounterfeiting interface public members encourage role transgenic animals measures products kenya exchange information counterfeit number biomedical research tanzania code included back products pharmaceutical industry caf sr ee sported use nonhuman primates nhps packs sent via text message tollfree customs bodies gsk one first number discovery development medicines number mobile service looks code companies sign helped pilot raids vaccines sends verification text back system number counterfeiting healthcare products arrests consumer product genuine pharmacovigilance initiative received george didomizio significant seizures industry award usa recognition result cooperation china companys efforts business partner one operation led raids nine underground project prevent spread facilities guangzhou seizures counterfeit medicine including counterfeit gsk antibiotic tablets intended west africa china introduced separate case china operators capability put serial numbers packs counterfeiting factory guangdong pharmaceutical products allowing province sentenced lengthy jail terms electronic monitoring patient safety faking different medicines valued purposes chinese governments including doses system result serial numbers panadol caplets intended middle east introduced packs heptodin medicine combats hepatitis b lessons learned technology china help us implement similar initiatives elsewhere worldgsk corporate responsibility report public policy patient advocacy public policy goal demonstrate applications new incentives antibiotic moment significant regulatory interactions political stakeholders research increased staff levels reforms implemented andor advocacy work patient advocacy groups conducted training rare diseases therapies planned eu china make valuable contribution appropriately ethically transparently advocated reauthorisation called g governments develop debate issues impact provide clarity approach pandemic allhazards preparedness act incentives reward products lower developed set criteria guide public health business improve preparation public environmental impacts supportive choose public policy groups health emergencies usa public procurement policies influence regulation work advocated support safe doses act trade association membership aim take advocacy work support commitment strengthens usa law enforcement responsible approach access innovation explained system fight medical theft protect member many trade industry health section associations membership groups guided values patients risks associated resold support efficiency effectiveness key public policy engagements stolen improperly stored medical protect interests patients public policy work link provides list included following products including medicines reentering memberships trade associations supply chain usa much focus primarily represent pharmaceutical consumer transformation usa healthcare worked trade associations ensure product vaccine businesses national system also submitted comments proposed changes european regional international levels list federal agencies implementing commissions data protection regulation updated regularly affordable care act signed guarantee appropriate levels privacy political contributions law comment process patients study participants successfully advocated changes impede meaningful biomedical research make corporate political ensure appropriate access patients urged european union heads state contributions implementation law continue find sustainable approach control employee political action committee next decade significant pharmaceutical costs minimises provisions coming effect effects austerity measures usa employees choose make engaged federal state availability medicines personal political contributions governments policymakers healthcare gsk employee political action committee professionals payers ensure law advocated establishment federal pac facilitates voluntary political prioritises quality encourages valuebased drug regulatory authority pakistan contributions eligible employees healthcare system maintains incentives allowed drug regulatory accordance federal election pharmaceutical innovation supports process start functioning campaign act gsk employees access medicines vaccines nearly year inactivity pac contributed republicans advocated passage food drug worked european chinese industry democrat candidates running administration safety innovation act authorities strengthen euchina state federal offices fdasia usa allows regulatory cooperation alignment improved processes review druggsk corporate responsibility report public policy patient advocacy continued lobbying expenditure patient advocacy working patient groups state case study among things country must costs associated lobbying eu patient groups nonprofit organisations nominate senior member staff responsible institutions range founded patients caregivers family leading coordinating patient advocacy european patients outlined european members health professionals activity general manager academy therapeutic transparency register figure includes important stakeholders us engage country must meet least two patient groups innovation running brussels advocacy office salaries healthcare providers governments year external events travel accommodation media patients promote improved consulting costs educational materials treatment services patients also publish information work involved creation takes account proportion campaign issues affect patients patient groups online europe asia european patients academy employee time spent representing gsks caregivers lives carry research pacific emerging markets regions well therapeutic innovation eupati interests eu institutions excludes trade causes potential treatments information support patient patientled consortium association membership fees specific conditions groups working globally including details organisations increase capacity funding received patients effective advocates usa spent federal relationships patient groups help advisers clinical trials regulatory lobbying activities us better understand patient needs also voluntarily disclose funding authorities ethics committees see usa federal lobbying register illnesses guides rd turn support us website detailed eupati provide includes costs salaries benefits support helps patient opinions heard information gsk australia canada seven languages european employees registered lobby us found websites provide funding patient groups help countries educational materials government use lobbying consultants daytoday running costs defined patient advocacy leaders summits research development processes support lobbying contacts planning events activities support also includes ten years patient advocacy leaders medicines also create public library activities research running gsk educational assistance training staff summits pals bringing patient medical rd member washington dc government affairs office eupati consortium contributing collaboration disease awareness advocates together discuss health policy support staff portion trade expertise staff time funding prevention projects develop new skills ways expand association fees associated federal lobbying influence usa gsk employees relevant third parties national pals washington dc well work patient groups must follow eight regional pals throughout country guidelines standard operating procedures focusing patient advocates role sops example limit amount implementing healthcare reform elsewhere funding provide patient held pals bulgaria finland groups overall funding state netherlands germany portugal slovakia relationships patient groups must never middle east africa regional pals linked promotion products qatar since excess people also provide training employees representing around organizations understand requirements countries participated european operating companies pals required apply new minimum standardsgsk corporate responsibility report approach tax businesses increasingly understand responsibility pay took decision centralise transfer pricing line oecd appropriate amount tax time pharmaceutical intellectual property guidelines base transfer pricing policy challenged ensure responsibility shareholders product inventory ownership uk arms length principle support contribute financially efficient deliver move helps us decrease administrative transfer prices economic analysis tax system societies sustainable tax rate also support efforts complexity involved multiple owners reports worldwide nature ensure companies appropriately intellectual property within business operations means rd operate transparent tax affairs also deliver supply chain working manufacturing operations centred provide information managed capital efficiencies number key locations consequence crossborder supply routes tax management contribution substantial changes also made possible necessary ensure supplies medicines principles policies business employment presence many introduction new patent box tax rules numerous endmarkets complex countries around globe pay uk government rules make significant amount tax including corporation uk attractive place locate ip tax havens engage artificial business taxes well tax associated investment decision centralise ip tax arrangements without business employees example total fund rd uk means commercial substance policy last ten years paid approximately medium term expect pay use locations substantial billion corporation tax globally corporation tax uk business presence substantial local value generate sales pipeline business presence vast majority global corporation tax charge products created uk territories operate whether core profits approximately billion subject uk tax business offices sales force manufacturing group tax rate profits rd facilities local distribution means corporate tax relationship tax authorities gsk seeks products contribute economic due core profits around world maintain open positive relationships development create shared value amounted nearly one quarter total governments tax authorities worldwide region business core profit made year welcome constructive debate details corporate tax charges taxation policy held bilateral internal processes robust internal year set annual report discussions hm revenue customs policies processes training compliance hmrc uk internal revenue programmes ensure alignment pay considerable amount tax uk service irs us commercial across business meet tax given group sales generated terms centralisation obligations audit risk committee country significant ahead time agreement tax payer proportion global corporate functions pharmaceutical intellectual property ip board responsible approving tax authority appropriate transfer pricing methodology uk referred result tax strategy management certain transactions fixed period time rd manufacturing activities agreed enter bilateral advance pricing underlying principle transfer pricing even though two located uk addition corporation agreement irs hmrc companies within group act tax profits generated employment independent enterprises means companies must provide long term certainty appropriately rewarded assets employ value activities create subject risks assume entering intragroup transactions authorities gsk tax treatment ensure profits generated taxed countries number uk taxes including costs related move value arises appropriate reward considered reward indirect tax employment taxes would obtained third party known arms length principlegsk corporate responsibility report people people section overview talent development focus inclusion diversity engaging employees pulse programme gives employees like health safety wellbeing megha chance contribute expertise reward recognition widen horizons working nonprofit organisation case save children read gsk corporate responsibility report people focus pulse programme gives employees need people develop chance contribute expertise giving develop leadership skills widen skills appreciate different perspectives horizons working non people profit organisation highly motivated engaged chance nearly employees taken opportunity work full time resilient give back nonprofit organisation charity three six months funded gsk megha marketing gain people attract best team india undertook threemonth assignment save children helping thrive individuals aim ensure working charitys digital media valued supported empowered successful personally team used expertise help professionally want feel proud work save children communicate company work difference make work raise awareness issues addressing gsk strives inclusive accessible attractive employer pulse assignment gave megha pulse gave people backgrounds global footprint changes opportunity apply skills opportunity make work ensure continues reflected workforce contribute cause felt strongly impact megha used marketing clear values govern business responsibly little way experience help share stories children made strong public commitment values whose lives transformed megha work done save children ask every one employees live embody values gsk marketing team india reinforce training communication returning gsk megha able bring back passion experienced recognise reward performance apply work focusing help employees remain healthy resilient better patient save children also seen increase donations result management health safety programmes designed raising charitys profile online improve working environment engaging public social mediagsk corporate responsibility report overview glance talent development people employ emerging commitments markets asia pacific japan regions recruited graduates globally making represent total workforce c ontinue promote inclusion diversity e xtend volunteering opportunities progress towards target recruiting globally gsk bring positive change graduates year communities global health see continue create working environment providing individual development see inspires people grow perform healthy resilient way launched project search uk help empowered employees countries group young people learning volunteer nonprofit organisations disabilities make transition education countries pulse assignments world work gsk external perspective see see employee engagement gsk pioneered first business disability future challenges ensuring global employee survey said proud work gsk based forum us vision gsk take worldwide engaging participation equals level making easier employ business disabled applicants employees last survey disabled people company remains stakeholders meet needs committed focusing disability disabled older patients new products see global level within organisation developed packaged wider business community beyond gsk acted trailblazers inclusion diversity health safety wellbeing piloting project search uk transforming employability increased proportion reduced injury young people learning disabilities women management illness rate providing pulse volunteers bring see skills knowledge energy expertise see provided resilience training susan scottparker obe employees including advice reducing founding chief executive business disability forum stress improving energy levels httpbusinessdisabilityforumorguk see gsk corporate responsibility report talent development committed leaders managers early careers development community involvement employer want build capability leaders early career development programmes choice recruiting managers develop teams create include internships industrial placements two community involvement valuesbased culture demonstrate apprenticeships graduate schemes programmes pulse orange day retaining strong leadership global mba programme esprit enable employees develop skills talented people around broaden perspectives make engaging employees values accounts recruited graduates world developing valuable contribution outside gsk pulse significant proportion senior leaders making progress towards provides three six month assignments skills invest annual performance assessment line global target recruiting graduates employees work fulltime managers assessed deliver year new graduate programmes employees every nongovernmental organisation charity work well deliver launched communications human orange day programme gives level early careers leaders year undertake degree resources consumer healthcare units employees one paid day year volunteer assessments give direct line significantly increased number senior management chosen local community project managers opportunity provide detailed participants emerging markets feedback leadership behaviour addition since launch pulse nearly launched new esprit mba programmes people taken part recent focus enterprise leadership leading finance consumer healthcare commercial areas include malaria access healthcare business programmes aim help managers medical research development childrens health science education six widen perspective gain better months completing pulse nearly understanding diverse global business apprentices joined gsk bringing volunteers said energised healthcare challenges number apprentices uk work gsk example senior managers travelled across nine gsk sites continue assessed value pulse participants kenya india visit businesses hospitals commitment reimburse uncapped ngo partner organisations survey clinics learn societal tuition fees students recruited found increase retention rates among business medical challenges gsk companys uk graduate scheme volunteers compared gsk employee help solve population country around provide opportunities highpotential colleagues felt volunteers employees work closely members returning placements brought back corporate executive team reinvigorated energy spirit motivation future strategy group fsg examines morale teams addition challenging business issues affect gsk pulse ngo partners said volunteer met date employees taken part exceeded expectations employees completed fsg projectsgsk corporate responsibility report inclusion diversity inclusive introduced inclusive behaviours emerging markets employee perspective training usa programme focuses employer enables us uncovering participants unconscious biases aim increase proportion people better understand ensure behaviours consistent gsk emerging markets management respond needs values explains inclusion positions bring broader spectrum originally working gsk diversity increasingly critical backgrounds experiences people hr manager left rejoined patients healthcare success gsk employ emerging markets asia pacific take role hr director supporting workers markets women japan regions represent total gsk pakistan iran afghanistan workforce around senior managers helps us attract gave chance experience leading report corporate executive team percentage women higherlevel function first time two years later retain motivate regions eight different management positions continued grow offered opportunity work nationalities represented within workforce reflects reflecting ambition support employer brand project part ceos corporate executive team board gender equity senior levels future strategy group based gsk many communities one region shown marked progress leadership development programmes headquarters london onto operate asia pacific general carefully managed ensure singapore lead asia pacific talent work manager level women talented people parts world development project appointed opportunity participate vp hr middle east africa five nonexecutive directors women employees different nationalities tasked set area representing board exceeding participated leading business hub istanbul goal female programme designed develop future board representation three members summary career gsk general managers corporate executive team women fulfilling every day stretched emerging markets first line leadership representing team interact colleagues across world initiative delivered languages helps nurture grow countries global mba programme gsk great place work women management positions esprit includes participants employees empowered values different countries reflected ways working svp vp director manager total fariha vice president hr middle east africagsk corporate responsibility report inclusion diversity continued ethnic minorities disability case study ethnic minorities accounted uk want people disabilities able employees measure diversity access full range recruitment project search uk number employees career opportunities longstanding define nonwhite commitment number disability gsk became first private employees nonwhite compared organisations business disability sector organisation uk take forum uk sermes spain part global project search initiative helps young people learning proportion ethnic minority employees gsk launched project search see case disabilities make transition usa increased study right uk made education world work usa ethnic minorities defined black commitment focus disability global african american people hispanic level beyond see quote first intake students aged latino people asian people pacific islanders business disability forums founding chief joined employees corporate american indian people alaskan natives executive susan scottparker headquarters september year continue monitor benchmark work experience areas usa gsk become member industry standards defined restaurant security post room north american industry classification gettinghiredcom national talent search continue last year studies organisation people disabilities system pharmaceutical medicine project helps us think differently enhance opportunities hire manufacturing example potential young people talented people disabilities levels engaging external groups representing learning disabilities providing organisation minorities events like national work experience alongside fulltime black mba national society study dramatically increases chances hispanic mbas conferences southeast participants finding employment asian association conference council experience project participants advancement muslim professionals organisations suggest raises conference equal summit employment rates ethnic minorities uk usa employees uk usa number project search students gskgsk corporate responsibility report engaging employees strive engage keep employees informed capability area utilising gsks case study broadcasts ceo corporate change framework enable managers employees executive team articles intranet better support employees change values progress also equip senior leaders information getting involved managing change making need brief teams important games company news provide local context early announced expansion company employee survey major change programme first survey among employees showed listening views phase announced second sense pride working gsk employees shared views quarter programme focused increased following london gsks progress employee advancing technology reducing costs olympic paralympic games gsk survey participation rate improving efficiencies reallocating resources official laboratory services provider last games using scientific expertise conscious effect conducted survey survey results facilities support integrity restructuring employees aim communicated employees games health achieve organisational financial goals used business unit function competing athletes without eliminating positions redeploy address areas improvement ran global competition asking employees possible remain employees nominate colleagues favourable percentages two committed consulting changes via demonstrated olympic values areas gsk values employees number consultation forums well friendship integrity equality saying understand constitutes discussions european works council excellence received ethical business practices conduct similar bodies countries nominations markets job saying clear national practice jobs lost winners received tickets games accountable business change offer compensation role survey also found support outplacement line participants got involved employees felt gsk taking appropriate local requirements employment gold challenge fitness events raising actions socially responsible compared legislation also offer employees support charity events included global norm resilience training employee km challenge employees assistance programme cover km km km gsk undertaken significant business via range sports gsk teams changes recent years including new countries travelled combined distance acquisitions joint ventures outsourcing km site closures staff reductions markets favourable percentages area change management lower survey although slightly better global norm major organisations continue strive make improvements especially focusing developing leadershipgsk corporate responsibility report health safety wellbeing aim create working communicate effectively healthy highperforming employee perspective employees health safety simplified resilient workforce environment inspires online health safety information supports people made consistent across energy performance personal grow perform safe business streamlining health resilience ep training programmes provide partnership prevention safety policies standards reduce employees support reduce stress great initiative think going healthy resilient way bureaucracy make easier part work home improve energy mind shift part business focus key priorities levels productivity additional world used treatment employees took part one prevention great idea wife wants health promotion resilience programmes study know become disease prevention ep graduates us sales force showed advocate programme increase productivity eight gsk became first multinational calls per month achieved comparison gsk employee employer commit provide comprehensive consumer healthcare nigeria control group preventative healthcare services employees dependants worldwide programmes manage attendance next five years commitment ensure employees receive proper medical read online part mission help people care support help return work feel better live longer safely quickly usa attendance publish detail online key called partnership prevention new management programme saved approximately issues including million reducing time away programme provides access affordable hazardous chemical management work due disability returning healthcare prevention services gsk reach employees work sooner industry employees even countries healthcare average measured employer measures provision expensive inadequate productivity absence quality programme expand access services including immunisation cancer screening smoking cessation programmes hiv screening treatment covered health insurance services provided community healthcare networks gsk sites programme piloted among employees gsk employees families assured ecuador ghana nigeria romania results additional allow us develop global approach employees took part one resilience programmesgsk corporate responsibility report health safety wellbeing continued zero harm help embed safety culture data summary injury illness data focusing reporting near miss incidents goal zero harm employee enables us learn mistakes injury illness rate decreased hours worked millions achieve first goal eliminate prevent accidents routinely perform audits compared slips trips falls fatalities serious incidents risks employees vary ensure reducing managing risks leading cause injuries illnesses number injuries illnesses according roles include chemical effectively reviewed health safety accounting nearly incidents lost time exposure driving accidents repetitive commercial businesses result calendar days lost strain injuries extending network leading causes gsk reportable injuries number injuries illnesses illnesses without lost time four serious incidents environmental health safety coordinators losttime injury illness rate gsk globally two commercial sales globally per hrs worked employees died motor vehicle accidents continue embed risk reduction c pa ele r n r ys h l ro ss w r oa rt ke e routine calls physicians one programmes zero access reportable injury illness rate incident occurred india machinery respirator free initiatives per hrs worked argentina result driver safety aim minimise risk injury notes programme expanded two serious accidents reduce exposure data covers employees contract workers directly manufacturing sites machineryrelated harmful airborne powders deployment ilu lnp ee sr sv pis ee rd f ob ry g nk ce e fm orp tlo hy ee ye es rw ce r se ep mrt bn ea ap dsh et af f tin ej ru tr hy e en nd incidents resulted finger amputations process safety management system slipstripsfalls year data prior years may change one incident occured china prevent catastrophic events e mrg ao chn io nm eryic l ilo lns et st sim ese hin aju r aie res sa en rd io ulln e es ns oe us ga hre ow ro er sk ur lte il nat oed n ein oju r r mie os ra en dd ys belgium following rootcause analysis fires explosions releases hazardous motor vehicle la ow sa c afr leo nm aw r dr ak days including weekends investigation machinery safety substances remains target contact sharp objects employees could work workrelated injuries specialist tianjin site china illnesses indicates severity injuries illnesses r eportable injuries illnesses without lost time incidents corrective action plans developed result time away work teleconferences held review lessons reportable injury ilness rate learned vaccines facility belgium per hours worked environment health safety data reinforced equipment safety report assured bureau veritas training implemented comprehensive read assurance statement preventative maintenance plan response assured targetgsk corporate responsibility report reward recognition open executive pay pensions case study remuneration practices management executive level proposed pension benefit change ensure reward remuneration aligned business uk cap basic salary increases pa thinking locally performance measures designed employees uk definedbenefit plans based performance reward longterm performance terms increase would think locally comes pay reinforces values sustainable shareholder value otherwise provided would take benefits creating packages form nonpensionable salary supplement attractive competitive board level remuneration committee engaged consultation local location vietnam example sets remuneration policy levels national basis including provide loans employees cover corporate executive team responsibility manufacturing trade unions output purchase new motorcycle ensuring rewards appropriate consultation able make registration tax insurance three competitive industry wider market amendments original proposal years gives employees reliable norms annual report details total proposed change take effect form transport provides us remuneration earned available considering cost management advantage attracting executive directors changes benefits seek retaining talent putting values continue strike right balance heart rewards company employee interests fairness equity continue align employee rewards benefits reflect values aim provide consistent fair reward different ways appropriate across global locations tailor benefits developing countries market suit local circumstances see case study access unit dcma set increase among senior employees patient access gsk medicines vaccines structure bonuses longterm incentives building sustainable business consistent regardless location leastdeveloped countries objectives rewards managers unit based primarily volumes rather profit help ensure medicines reach need see also behaviour sales marketinggsk corporate responsibility report planet focus reducing carbon footprint greener methods making antibiotics read section overview carbon water waste managing impacts engagement data summary summary assurance statement gsk corporate responsibility report planet focus amoxicillin one widely growing business bring prescribed antibiotics world sustainable gsk manufactures around billion tablets innovative medicines people year antibiotics third largest antibiotics carbon footprint products around world committed based sales projections footprint increase reducing environmental traditional process synthesise amoxicillin requires energyintensive cooling large volumes organic solvents create impact waste however green chemistry team site singapore developed way using enzyme could environmental sustainability priority gsk effects cut carbon emissions process climate change water scarcity could undermine hardwon tonnes reduce organic waste around tonnes improvements global health natural resources rely produce medicines products becoming enzyme couples two compounds together water form amoxicillin using scarcer expensive stakeholders expect us manage fewer steps less cooling fewer organic environmental impacts responsibly solvents traditional chemical goal reduce process innovation makes important reducing footprint using resources efficiently carbon footprint contribution goal reduce working others tackle challenges reduce costs across business carbon footprint across business build competitiveness create trust business antibiotics sold highly competitive market improvements set ambitious goals reduce carbon water waste across also help differentiate product value chain use raw materials impacts announced plans invest million singapore dollars suppliers footprint labs factories use converting enzymatic amoxicillin disposal products patients consumers meet manufacturing quality road site goals must involve employees partners singapore read onlinegsk corporate responsibility report overview glance carbon established inhaler recovery recycling commitments external perspective service uk usa chile collecting despite reducing carbon energy use used inhalers uk reduce overall carbon footprint since total carbon footprint vs excluding raw materials see carbon neutral value chain companies organisations increased driven higher inhaler sales reduce water impact across public private closely examining value chain vs add social business see value operating within financial reduce operational waste environmental limits gsk risen vs challenge committed water build sustainable supply lines examining environmental footprints nutrition portfolio work local reduced water consumption products services moving farmers improve agricultural operations compared forward gsk need improve practices improve yields competitiveness livelihoods environmental efficiency products see services time acknowledge may need adapt managing impacts core business move towards services created green chemistry promote protect health performance unit research ways replace hazardous chemicals processes lower impact alternatives see pledged million establish centre excellence green chemistry collaboration university nottingham uk waste see cut total waste sent less waste landfill compared engagement see engaged suppliers david pencheon carbon water director nhs sustainable development unit waste reduction httpwwwsdunhsuk see gsk corporate responsibility report carbon longterm goal understanding co value chain carbon footprint million tonnes per annum tpa value chain carbon neutral means raw materials need look every estimate impacts supply chain raw estimate materials source account carbon process associated million tpa footprint products working suppliers help reduce impacts use resources efficiently products sourcing raw materials manufacturing operations co generated operations use product disposal operations generate co emissions mainly includes energy production energy use accounting around products co related emissions hfaa total carbon footprint looking ways make inhaler manufacture plus emissions processes efficient use less energy million tpa absolute emissions operations transport transport logistics co generated transport logistics inhaler use generate emissions business travel aim minimise transporting products logistics sales force co carbon footprint increased business travel customers excluding contribution raw materials million tpa reduced carbon energy use since increased inhaler metered dose inhaler use co generated metered dose inhaler use sales resulted rise carbon since emissions associated use metered inhaler use dose inhalers account value chain co million tpa carbon footprint co product use emissions associated use products boiling water make horlicks patients estimate use products eg boiling water customers account around overall footprint horlicks million tpa end life assured emissions disposal products make less carbon footprint inhalers biggest disposal impact starting collect inhalers recycling million tpa reduce see contributions based assuming value chain footprint million tonnes cogsk corporate responsibility report carbon continued performance achieved upgraded onsite power generation case study global certification carbon trust facilities combined heat power plants standard certifies across operating units across company making yearonyear overall sites saved tonnes co cutting carbon footprint horlicks reductions emissions associated equivalent per year approximately operations transport time period energy needs supplied renewable horlicks nutritional drink additionally introducing gsk multinational sources energy sites second largest source carbon emissions lowcarbon biomass energy generation achieved standard date product range inhalers horlicks factories using waste wood continuing research specific aspects estimated tonnes co replace coal expect performance carbon footprint help us identify cut emissions horlicks save tonnes co equivalent opportunities reductions end take important step towards meeting annually carbon footprint excluding completed carbon footprint climate change goals contribution raw materials analyses products currently measure annual basis analysed carbon footprint identified changes could reduce emissions increased compared horlicks found milk manufacture use focusing reduced carbon footprint energy production accounted half projects potential achieve operations compared emissions across value chain tackle significant reductions ignore increased sales resulted rise carbon went back source buffalo opportunities make smaller changes footprint product transportation use dairy cows enhancing established together add big savings disposal metered dose inhalers indian government programme help account approximately value participate carbon disclosure farmers learn modern milking chain carbon footprint increased inhaler project investorled initiative aimed techniques giving access sales resulted rise greenhouse improving transparency around corporate better veterinary care increasing milk production per cow gas emissions inhaler use compared carbon emissions report annually reduce overall carbon footprint however carbon reduction project policies programmes projects underway enable us performance area details seen reach interim target cut value cdp website chain carbon footprint million also collaborated organisations tonnes co equivalent national health service sustainable development unit association british pharmaceutical industry develop carbon footprinting guidance pharmaceutical companies assured bygsk corporate responsibility report water waste minimising waste water following suggestion employee waste instead pulling fresh water local water use helps reduce gsk signatory un ceo water supply stage water recycled reduced amount total environmental footprint mandate initiative help companies saving around million litres every year waste hazardous nonhazardous improve efficiency develop implement disclose sustainable water used plant compared making progress towards water practices targets cut waste save money protecting nabha india another waterstressed demonstrates commitment region staff achieved limited natural resources working governments civil society reduction water use since also reduced waste sent landfill stakeholders protect fulfil million litres million litres compared working towards goal human right water defined united measures included making sure water zero waste landfill total nations particular reducing use measured metered using manufacturing sites send waste water consumption parts world pressure hoses general cleaning landfill made reductions make biggest difference reusing treatment water watering plants number measures including developing longerterm water strategy recirculating cooling water recovery solvents used input ngos build commitments manufacturing active pharmaceutical made water mandate plan respond annually cdp water ingredients improving waste segregation launch disclosure project investorled initiative across plants offices supports sustainable corporate water use fresh water manufacturing processes management latest submission within products drinks project found cdp website vaccines around value chain water footprint associated sourcing raw materials instance milk used net water consumption operations total waste generated products horlicks million cubic metres thousand tonnes target reduce impact water consumption across value chain end think important cubic metres excludes nonroutine start operations asking waste construction demolition others change least learn valuable lessons shared suppliers total waste many effective ideas reducing water use target assured come employees especially water stressed areas example plant port fairy australia water required three stages manufacturing process target targetgsk corporate responsibility report water waste continued waste landfill hazardous waste incinerated tonnes packaging using survey responses suppliers per year saving tonnes thousand tonnes co equivalent packaging used products highly oto u rd te rgti ef ty prioritise actions meet visible patients consumers aim mass efficiency use paper packaging materials made continue recycle pet packaging wood grown harvested trays used deliver components sites made progress improving responsibly surveyed suppliers ware uk evreux france means mass efficiency measure carton board packaging corrugated packing purchase less recycled pet open market waste landfill amount raw materials required make target leaflet paper rainforest alliance make ribena bottles make using new active pharmaceutical ingredient developed internal policy recycled pet weighted account scale manufacture prioritise larger scale processes introducing new chemistry solvent recovery case study biggest benefit mass efficiency figure represents snapshot performance inhaler recycling programmes target one products transferred manufacturing large scale process recovering solvents patients finish gsk inhalers flowerpots remaining gas developed solvent recovery process resulting inhalers usually end landfill waste captured metal components water excluded solvents make average mass efficiency complete cycle new recovery recycled material used make lower volume products transferred recycling programme aimed reducing also inhaler recycling schemes active pharmaceutical ingredient use mass efficiency slightly lower waste uk expanded chile exploring options around tonnes solvents year still good improvement pilot programme collected australia japan czech republic recover reuse mass efficiency primary processes weo r vh ea sn v e n toh na nle er ss w f ce e ti om da te e h hungary nordic countries reusing solvents significantly reduce making complete cycle manufacturing also working waste save money disposal available across uk supplier presspart group use buying new solvent recycled aluminium cans ventolin usa expanded similar seretide advair flixotide metered dose continue look opportunities programme five cities inhalers possible result carbon manufacturing instance participating pharmacies receive kits emissions producing cans gsk introduced recovery diisopropyl ether include special containers customers reduced around tonnes solvent ulverston uk drop inhalers pharmacies supplied manufacture antibiotics reduce prepaid envelopes inhalers co equivalent per year sent freeofcharge specialised assured recycler plastics used make new household products plastic target co savedgsk corporate responsibility report managing impacts addition priority green chemistry chlorofluorocarbon cfc refrigerants compliance fines focus areas carbon water green chemistry aims replace hazardous working towards eliminating fines reported year waste manage chemicals processes inventory chlorofluorocarbon cfc internal audit smaller environmental impact refrigerants deplete ozone layer range important audit operations make sure created green chemistry performance unit removed environmental issues put green chemistry theories practice remaining cfcs tonnes disposing environmental risks impacts identified managed effectively unit published internal guides two large pieces chilling equipment need audit determined based help employees make better chemical choices cfc recovered safely destroyed business knowledge modelling risk designing developing products selling building contained two indicators trends previous audit large chiller units third party means year formalised million findings team responsible auditing low volumes cfcs collaboration university environmental health safety ehs collectively less kg small pieces nottingham uk establish centre certified iso environmental equipment various sites across world excellence green chemistry management lead auditors disposed safely time construct carbon neutral sustainable equipment decommissioned ehs audits sites chemistry laboratory centre scheduled completion remediation globally across different business units audits included review encourage development cleaner waste disposal industrial activity environmental management systems safer efficient processes contaminate soil surface ground water management environmentally pharmaceuticals environment gsk takes responsibility environmental hazardous materials waste water remediation work facilities used audited theme across manufacturing sites pharmaceuticals always completely previously disposal sites waste resulting number improvements absorbed broken body management companies used residues find way read ehs audits key suppliers gone business environment excreted unused supply chain section currently environmental remediation sites medicines disposed consumers around world gsk part policy statement pharmaceuticals sole responsibility environment available online continue participate research important spent million issue partnering universities environmental remediation estimated birmingham cambridge york future remediation work cost uk working industry trade approximately million assured associations european federation pharmaceutical industries associationsgsk corporate responsibility report engagement engagement engaging employees engaging suppliers employees suppliers need employees understand around carbon footprint lies read online helps deliver strategic environmental challenges face value supply chain must engage environmental objectives contribute teams individuals suppliers reduce environmental publish detail online key else achieve together impacts using carbon footprint analysis issues including environmental issues get employees involved set top products starting point climate change often complex global network sustainability advocates begun talk supply chain hazardous chemical management partners carbon water waste address employees typically volunteer take genetically modified microorganisms reduction asked data environment health safety ehs role enthusiasts promote effectively environmental footprints gsk reach sustainability among colleagues changing working together practices behaviours work home organised workshops work gsk convention biological diversity identify opportunities carbon savings nanomaterials advocates help establish waste reduction engaged key suppliers ozone depletion metereddose inhalers programmes encourage employees share environmental issues asthma good environmental practices promote pharmaceuticals environment community projects well increasing impact climate change health awareness many advocateled projects result use ozonedepleting substances savings gsk use social networking ancillary plant equipment encourage discussion generate ideas enable employees make new connections ceo also runs annual awards recognise contributions innovations teams around company environment health safety sustainability year entries sustainability award section assured bygsk corporate responsibility report data summary environment health safety data performance data summary report assured bureau veritas target read assurance statement change change note note since note response carbon thousand tonnes coequivalents per annum detailed breakdown metrics carbon footprint note note note data please see download climate change impacts available online raw materials note note operations operational energy sources note operational energy transport product transport note note employee air travel sales force vehicles inhaler use patients water million cubic metres water use operations waste thousand tonnes total operational waste generated total operational waste landfill values restated previous report estimated data included actual data available reassess carbon footprint across value chain annual performance available investigated use phase products partnership university manchester uk estimated use products including inhalers adds approximately million tonnes coe value chain footprint revised emission factor used refrigerated cargo ocean transportation one published nd international marine organisation imo ghg study restated data sources include co equivalent impact inhaler production losses leaks chillers productionrelated releases waste treatment related releases baseline assured bygsk corporate responsibility report summary assurance statement basis reporting sites selected review scope methodology included gsks response assurance external assurance gsk businesses sitespecific audits assessment ehs data associated data conducted six sites data verified management processes involved detailed pleased bureau vertitas energy co emissions data collected back source special focus review integrity selected datasets findings gsks progress managing pharmaceuticals sites top contributors data aggregation checking processes reducing ehs impacts committed consumer healthcare manufacturing sites environmental emissions previous year corporate level well sampling data continued improvement ultimate vaccines sites pharmaceuticals sites previously visited back source six gsk sites sites goal providing accurate ehs data consumer healthcare rd sites uk prior years sites difficulty chosen represent manufacturing sites public website headquarters building offices submitting data timely manner greatest emissions range different continue work toward improving distribution centres water nonhazardous gsk operations ie gms vaccines data accuracy emphasis bureau veritas summary waste data collected rd geographical spread interviews incorporating recommendations provided independent assurance statement manufacturing vaccines operations also undertaken ehs directors bureau veritas rd major office locations based bureau veritas uk ltd engaged understand gsks sustainability strategy read gsks full response assurance materiality assessment collect gsk provide independent assurance objectives targets implementation plans hazardous waste wastewater data environment health safety ehs data progress offices sites manufacture consumer related information within people bureau veritas opinion gsks healthcare nutritional products planet sections corporate corporate responsibility report demonstrates volatile organic compound vocs responsibility report report pages understanding ehs material issues reported sites manufacture undergone assurance indicated gsk generally made good progress pharmaceuticals contain rd pilot plants bureau veritas logo comment managing reducing ehs impacts use greenhouse gas protocol assured bureau veritas full assurance report provides fair summary ehsrelated calculations co emissions statement found includes full activities performance metrics data energy use propellants refrigerants details scope work methodology free omission significant error use co country factors electricity findings recommendations published international energy improvement full assurance statement includes agency recommendations improvement including refinement data collection processes first year bureau veritas uk ltd engaged gsk provide independent assurance environment health safety ehs data related information within people planet sections corporate responsibility report london february gsk corporate responsibility report governance engagement good governance governance boardlevel audit risk committee audit assurance transparent reporting focuses key business risk areas assess many aspects responsibility corporate executive team cet gsk including nonfinancial reputational performance internal part commitment headed ceo andrew witty accountable risks supported risk oversight external assurance processes audit open responsible management business compliance council rocc ensure assurance department responsibility overseeing relevant policies effective internal controls implemented independently assessing adequacy business activities also programmes gsk significant risks rocc chaired effectiveness management engage stakeholders directly cet members also participate board corporate compliance officer significant risk areas reporting outcomes understand prioritise level corporate responsibility committee includes least three members cet audit risk committee line crc crc provides highlevel guidance members include general counsel agreed assurance plan includes issues approach reviews policies company secretary head audit assessing sample basis process important progress crc assurance additional members added controls place comply laws members sir christopher gent chair appropriate regulations company standards across gsk dr stephanie burns dr daniel podolsky manage specific issues governance audit team recommends improvements lynn elsenhans joined october bodies sustainability steering team issues identified gsk managers crc meets four times year consisting senior leaders across develop action plans address causes frequently necessary reports senior business bring perspective gsks noncompliance gaps internal controls managers members cet enable different businesses environmental debates audit assurance tracks plans members review ensure progress shape environmental strategy making completion reports results senior responsible management business sure intergrated management audit risk committee committee reports findings read assurance internal audit board year summary risk management governance section cr committee report contained annual report annual report see annual report detailsgsk corporate responsibility report governance engagement continued stakeholder engagement meetings investors discuss aspects reporting gsks responsible business strategy engagement dialogue enables us report performance annually understand needs key stakeholders employee survey received report part commitment open keep touch views feedback responses respondents transparent business activities allows us identify important issues participation rate gave responsible business also covered current emerging shapes us valuable insights staff views annual report responses issues ensure strengths weaknesses gsk reporting standards best interests wider society well see global reporting index shows shareholders also helps build broad range engagement ngos elements guidelines covered trust gsk international organisations governments report member un global engagement takes place policymakers better understand compact gsk also publishes index normal course business daytoday issues around increasing access show reporting line interactions customers employees healthcare sustainable way global compact expectations suppliers partners also carry acted cochair uks industry formal structured engagement government forum access medicines data coverage including meetings consultations participated partners forum data report relates worldwide surveys participation conferences uk governments global health strategy operations calendar year debates provide training help managers attended executive board meetings except otherwise stated data markets communicate local world health assembly participated environment health safety stakeholders approach responsible board members gavi alliance sections independently verified business transparency roll back malaria partnership engaged bureau veritas brand names appearing intergovernmental meeting italics throughout report examples engaged stakeholders pandemic influenza preparedness trademarks owned andor licensed included throught report addition gsk associated companies undertook consultation non governmental organisations global public health groups socially responsible investors sustainability think tanks gsks existing future responsible business commitments included roundtable meeting interviews survey facilitated business social responsibility helped shape promises goals see wwwgskcom feedback counts find downloadable pdfs welcome feedback responsible business performance reporting annual report please let us know would like receive annual summary regular updates progress form f csrcontactgskcom corporate responsibility report head office registered office also search us glaxosmithkline plc great west road brentford middlesex tw gs united kingdom tel registered number photocredits front cover health divider marcus perkins behaiour divider getty images people divider tom whipps planet divider getty images